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Cell damage represents a major pathomechanism in many diseases of high clinical 
interest, such as myocardial infarction (MI), where it plays an important role in ischemia-
reperfusion (I/R) injury. Considerable progress has been made towards identifying 
physiological and pharmacological agents that play a key role in myocardial 
preconditioning against I/R injury and also elucidating the molecular changes leading to 
such protection. 
Second messengers in cellular signaling pathways, such as cGMP have been well 
implicated as key players in ischemic and pharmacological preconditioning (PC) of the 
xii 
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heart. Phosphodiesterase type 5 (PDE-5) is an enzyme that specifically hydrolyzes cGMP 
thereby decreasing its tissue concentration. Sildenafil is a potent selective inhibitor of 
PDE-5 and therefore allows the accumulation of cGMP in several tissues shown to express 
PDE-5, including pulmonary and coronary arteries. We initially hypothesized that 
vasodilation induced by sildenafil may release several endogenous mediators including 
adenosine, bradykinin or nitric oxide (NO), that may trigger a signaling cascade leading to 
protection against ischemia/reperfusion (I/R) injury. Our results show that sildenafil, at a 
clinically relevant dose, induced powerful acute and delayed cardioprotection against I/R 
injury in an in vivo rabbit model via opening of mitoKATP channels. The acute 
cardioprotective effect of sildenafil was dependent on activation of protein kinase C in 
rabbits. Moreover, we observed that sildenafil induced delayed PC by NO produced 
through activation of inducible nitric oxide synthase (iNOS) and endothelial nitric oxide 
synthase (eNOS) in the mouse heart. The expression of iNOS/eNOS was regulated by 
ERK phosphorylation and the delayed protection against I/R was blocked by PD98059, a 
selective ERK inhibitor. Furthermore, sildenafil-induced delayed protection was abolished 
in the intact heart as well as adult myocytes derived from adenosine A1 receptor knock-out 
mice suggesting an essential role of A1 receptor in protection. Taken together, these 
studies suggest that sildenafil is a powerful tool to reduce I/R injury in the animal models. 
Future clinical studies with relatively safe and effective PDE-5 inhibitors may have an 
enourmous impact on the use of these compounds in reducing I/R injury in the heart and 
other organs. 
   
 
 
 
 
CHAPTER 1 
 
INTRODUCTION 
 
1. Background 
   
Determining the mechanism(s) of cardioprotection in diseased hearts is of high 
significance because the mortality and morbidity of heart disease are increasing around the 
world, and there is a continuous demand for safe and efficient preventive or therapeutic 
strategies. Following the development and application of percutaneous transluminal 
coronary angioplasty (PTCA) [4] and percutaneous transluminal coronary recanalization 
(PTCR) in the clinical setting, treatment of patients with acute coronary syndrome has 
made significant progress [5]. As a result, mortality related to acute myocardial infarction 
has decreased, but the functional recovery of reperfused hearts is unfortunately less than 
expected, resulting in an increase of patients with chronic ischemic heart failure [6]. As of 
yet, no sufficiently effective drugs to decrease infarct size and prevent cardiac remodeling 
in patients with acute myocardial infarction or ischemic heart disease have been identified . 
Cardiologists involved in the management of patients with acute coronary 
syndrome, including severe unstable angina and acute myocardial infarction, occasionally 
used to report "the cardiac warm-up phenomenon" [7], in which patients with at least one 
episode of angina showed less severe ischemic damage after subsequent exposure to a 
1 
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longer period of ischemia. In 1986, Murry et al. [1] first documented this phenomenon 
experimentally and termed it "ischemic preconditioning" (PC). Following this initial 
report, numerous studies were performed using various tissues and animals (e.g., liver [8], 
kidney [9], brain [10], and endothelial cells [11]). PC was shown effective against 
subsequent lethal ischemic insults in all models. More importantly, PC has also been 
shown to occur in humans by some clinical studies [11]. This realization is highly 
significant due to the possibility of transferring some or all of the basic research findings 
from experiments involving PC to the clinical forefront in order to minimize infarct size 
resulting from ischemic injury in patients with cardiovascular disease. Brief periods of 
ischemia that cause preconditioning must occur prior to sustained ischemia to achieve 
cardioprotection, but induction of myocardial ischemia is not a practical treatment for 
patients with ischemic heart disease or those at risk of cardiovascular disease. Therefore, it 
is important to determine the mechanisms underlying ischemic preconditioning in order to 
devise new strategies effective against ischemic insults. Identifying some of the triggers, 
mediators, and effectors of ischemic preconditioning would make it much easier to develop 
more effective therapeutic interventions for acute coronary syndrome. Accordingly, 
research in this field has been aiming at recognizing the histological, biochemical, and 
physiological changes in the myocardium induced by ischemia in order to provide ideas 
about the cellular mechanisms of ischemic preconditioning. Thus far, intensive research 
has led to considerable progress in understanding the fundamental nature of ischemic 
preconditioning and many of the potential pathways involved.   
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2. Windows of Protection 
 Soon after the original studies on ischemic PC revealed its potent cardioprotective 
effect against I/R injury, independent reports from two laboratories in 1993 demonstrated 
that the cardioprotective effect of ischemic preconditioning on infarct size was still 
detectable for 24 hr after preconditioning and was associated with increased expression of 
high molecular weight heat shock proteins (HSPs) [12, 13]. Because Kuzuya et al. [12] 
also found that the infarct-limiting effect of preconditioning dissipated between 3 and 12 hr 
after a brief period of ischemia, these two periods of cardioprotection were then referred to 
as the "first window" and "second window", respectively, which are now known as "early 
phase (or classical)" and "late phase" preconditioning. Subsequent research on the late 
phase of cardioprotection afforded by PC also showed that it can persist for up to 72 hr 
after preconditioning [14]. Thereafter, studies on PC focused on investigation of the 
subcellular mechanisms, with the aim of devising new methods for application to 
pharmacological preconditioning and for new clinical therapies to control acute myocardial 
infarction and the resulting damage to the myocardium.  
Interestingly, although different mechanisms may be involved in their mediation of 
cardioprotection, the "early phase" and "late phase" of PC were reported to share some 
trigger mechanisms. However, whereas the early phase is dependent on reactions that 
occur very rapidly, such as direct activation of ion channels or phosphorylation of enzymes 
and proteins, the late phase involves processes that require a longer period to occur such as 
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modulation of the genes regulating channel proteins, receptor proteins, enzymes, molecular 
chaperon proteins, or immune factors. So, in other words, it is quite interesting how these 
two types of cardioprotection that occur at different time windows might share certain 
triggers, mediators, and effectors. 
For the purpose of the current discussion, we decided to individually describe the cellular 
mechanism(s) involved in each of the two phases of PC. 
 
 
3. Early phase PC: Cellular mechanisms 
Adenosine 
A little over a decade ago, a study showed that inhibition of the adenosine receptor 
by administration of 8-p-sulfophenyl theophylline (8-SPT) prior to sustained ischemia was 
able to abolish the protective effect of ischemic preconditioning in a rabbit model [15]. 
This report suggested that adenosine was a strong candidate as an agent for 
pharmacological preconditioning and a trigger factor for ischemic preconditioning.  
Taken together with the facts that the adenosine A1 receptor is one of the typical G-protein-
coupled receptors (GPCRs) that have seven transmembrane domains, and that the 
intracellular Ca2+ concentration rises soon after the onset of ischemia, it was hypothesized 
that the subsequent cardioprotective response to an adenosine A1 receptor-derived stimulus 
is related to both G-protein signals and Ca2+. As a result of myocardial ischemia, there is 
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an immediate depletion in the ATP that is available for the cardiac cells [16] and as a 
consequence adenosine is released [17] to interact with its receptors. In this respect, it was 
believed that brief episodes of I/R would cause the release of adenosine and allow the 
interaction with its receptors to “precondition” the myocardium against future ischemic 
insults. Moreover, intracoronary infusion of adenosine in the isolated rabbit heart [18] or 2-
chloro-N6-cyclopentyladenosine (CCPA) in the isolated mouse heart prior to sustained I/R 
demonstrated a marked decrease in infarct size when compared to control animals. In 
addition, intravenous administration of another adenosine agonist, R-phenylisopropyl 
adenosine (R-PIA) also produced similar results following sustained I/R.  Furthermore, in 
a study performed on transgenic mice, it was shown that over-expression of cardiac A1 
adenosine receptor provided protection against I/R injury.  There appears to be a dose 
dependent manner in which these adenosine receptor agonists operate.  Whereas three 
doses of CCPA significantly reduced infarct size in the rabbit heart [19, 20]; continuous 
adenosine A1 receptor activation with a chronic infusion of CCPA causes down-regulation 
of the signaling cascade and the loss of the protective effect [21].  Despite these 
observations, the intermittent administration of CCPA 10 day period did in fact confer 
cardioprotection 48 hours after the last dosing [22].   
 
Protein Kinase C (PKC)  
 Protein kinase C (PKC) was first described as a calcium-activated, phospholipids-
dependent serine/threonine protein kinase. PKC is activated by diacylglycerol (DAG) 
6 
hydrolyzed from phosphatidylinositol (PI) by phospholipase C (PLC) under different cell-
signaling systems and has been an attractive intracellular receptor for tumor-promotor 
phorbol esters. Despite the fact that PKC has been implicated as a protein kinase, further 
molecular studies revealed that it belongs to a family of serine/threonine-specific protein 
kinases and is involved in diverse cellular functions, including cell proliferation, tumor 
promotion, differentiation, and apoptotic cell death.  
PKC consists of at least 11 isoenzymes with selective tissue distribution, activators, and 
substrates. Some of the isoenzymes are classified as classical or conventional PKC, which 
require phospholipids, DAG, or phorbol ester and calcium, and others were classified as 
novel PKC which share the same requirements with conventional PKC with the exception 
of calcium. More recently, a different class of PKC emerged and that is the atypical PKC 
which depends on phospholipid only. 
 Classical PKCs are activated by DAG and calcium in the presence of phosphatidylserine 
(PS) and constitutively present in the membrane as follows: (i) DAG and inositol-1,4,5- 
triphosphate (IP3) are generated from plasma membrane–associated phosphatidylinositol-
4,5-diphosphate (PIP2) by the activation of PLC; (ii) Ca2+ is released from an intracellular 
storage pool stimulated by IP3; (iii) Ca2+ is bound to the C2 region of PKC and the enzyme 
is subsequently translocated to the plasma membrane where (4) it is activated by DAG and 
PS. Phorbol ester, in this model, would mimic the action of DAG, and, by its persistence in 
the cellular membrane, lead to the long-term activation of PKC. As mentioned, nPKCs do 
not need Ca2+ for activation, but they do require DAG/PS or phorbol ester/PS. These 
processes are quite rapid, taking place in seconds or minutes, so that a more pronounced 
7 
activation of PKC is required for cellular response to growth factors, cytokines, and 
phorbol ester. Sustained activation of PKC is obtained by the long-term generation of 
DAG from phosphatidylcholine by phospholipase D (PLD). Phosphatidylcholine is 
hydrolyzed to choline and phosphatidic acid that is then converted to DAG by 
phosphomonoesterase, thereby activating PKC. Intriguingly, PLD is activated by PKC 
activators such as TPA and PKC itself. Furthermore, unsaturated fatty acids, such as oleic, 
linoleic, linolenic, and arachidonic acid, and lysophosphatidic acid produced from 
phosphatidylcholine by phospholipase A2, have been shown to enhance the activation of 
PKC by DAG. Cytokines such as interleukin (IL)-3 and IL-1 induce phosphatidylcholine 
hydrolysis, but not inositol phospholipids turnover; thus, the signal-induced production of 
a distinct second messenger or activator may decide which PKC isoform becomes 
activated or not.  
Evidence for a significant role for PKC-α in the prevention of the apoptotic process is 
increasing. Phosphorylation and activation of PKC- α are blocked by ceramide via 
activation of okadaic acid–sensitive protein phosphatase (ceramide activated protein 
phosphatase [CAPP]). Ceramide also inhibits both the translocation of PKC- α from the 
cytosol to the particulate fraction and activation of PLD, interfering with PKC-mediated 
activation of PLD. Cell permeable C2-ceramide inhibits activation of PLD and decreases 
PKC- α activity. PKC- α may prevent apoptosis via activation of Bcl-2, as (1) ceramide-
induced apoptosis is prevented by Bcl-2; (2) cPKC-mediated phosphorylation of Bcl-2 at 
serine 70 functionally suppresses apoptosis; and (3) PKC- α co-localizes with Bcl-2 at the 
mitochondrial membrane and phosphorylates it, thereby preventing progression of the 
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apoptotic sequence. PKC-ε is also postulated to function as a suppressor of apoptosis, 
because Bcl-2 is a substrate of PKC- ε. Overexpression of PKC- ε in human IL-3–
dependent TF-1 cells suppresses apoptosis induced by withdrawal of the cytokine via 
induction of Bcl-2 expression. PKC- ε appears to be inhibited in TNF-α-, Fas-, and 
ceramide-induced apoptosis, where the ε isoform is displaced from the particulate fraction 
to the cytosol. 
Ytrehus et al. [23] found that inhibition of PKC abolishes the limitation of infarct size by 
pretreatment with adenosine or by ischemic preconditioning, suggesting that PKC plays a 
pivotal role in the cardioprotective effect of preconditioning. Because PKC can be 
activated by either ischemia or by extracellular stimuli such as catecholamines (α1-
adrenoceptor stimulation), lipopolysaccharide (LPS), and PMA [24 and 25], thus leading 
to cardioprotection [26], it has come to be recognized as a major mediator of ischemic 
preconditioning.  
On the other hand, it has been reported that transient Ca2+ overload prior to sustained 
ischemia also has the same protective effect as ischemic preconditioning [25]. 
Furthermore, the cardioprotective effect of PKC is abolished by GF109203X, a selective 
inhibitor of Ca2+-dependent PKC (classical PKC) [27]. Because PKC-α is Ca2+-dependent, 
these data suggest that triggering of the early phase preconditioning may be closely 
associated with transient changes of intracellular Ca2+ during a brief period of ischemia. 
While investigations were performed to identify the responsible subtype(s) of PKC in a 
dog model [28] and a rat model [29], it was found that PKC-α mediates cardioprotection 
9 
due to preconditioning in dogs, while other isozymes such as PKC-δ [30, 31 and 32] or 
PKC-ε [33] have been detected in smaller animals. 
Ischemic PC, as initiated by brief separate episodes of I/R, causes the release of 
endogenous compounds such as adenosine, bradykinin, catecholomines, opioids which in 
turn instigate signaling cascades leading to activation of PKC. PKC can also be activated 
by reactive oxygen species which are known to be generated during short episodes of 
ischemia especially at the onset of reperfusion. PKC potentially activates certain 
transcription factors which play an important role in the synthesis of several proteins 
including indcible nitric oxide synthase (iNOS), antioxidants, Bcl-2 and stress proteins. 
iNOS generates NO and hence leads to the formation of cGMP from guanylyl cyclase 
(GC), and cGMP in turn may activate protein kinase G (PKG) leading to opening of 
mitochondrial KATP channels.  By preventing calcium overload and preservation of ATP, 
opening of these channels causes cardioprotection against I/R injury. 
Administration of PKC agonists in the isolated rat heart resulted in myocardial 
preconditioning [34].  However, PKC inhibitors given at the end of the ischemic PC period 
in vivo [35] blocked the protection of PC.  This reveals that there is a critical period at 
which PKC exerts its cardioprotective effect during sustained ischemia but not the PC 
stage [36].   
Since pertussis toxin pretreatment blocked the protective effect of PC [37], it was 
suggested that the A1 adenosine receptor coupled to the G-protein system is a key player in 
inducing cardioprotection by PC.  Other receptors including muscarinic M2 [38], 
adrenergic α1 [39], and bradykinin B2 [40] are also coupled to the G-protein system and 
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were shown to activate PKC and mimic the effect of ischemic PC [41].  A1 adenosine 
receptor-G protein- coupling activates phospholipase C which degrades phospholipids of 
the membrane to DAG. As a result, DAG activates PKC and causes its translocation from 
the cytosol to the membrane by the microtubules [42].  In deed, blocking this activity with 
colchicine abolished the effect of ischemic PC, demonstrating the importance of PKC 
translocation in PC [35].  Other studies also showed that it is not essential for PKC to be 
continuously activated in order to cause cardioprotection by PC; however, the 
phosphorylation of certain downstream proteins by PKC prior to sustained ischemia is 
necessary for achieving an infarct-sparing effect with PC.  
 
ATP-sensitive potassium channels (KATP channels) 
 Research involving ATP-sensitive potassium channels (KATP channels) has a 
longer history than studies on ischemic preconditioning, since their existence in the 
myocardium was first reported in 1983 [43].  
The KATP channel exists in the membrane and is modulated by Mg and ATP [44]. KATP 
channels were first identified by cardiovascular physiology studies as causing vascular 
smooth muscle relaxation in either large or small arteries or as having a negative inotropic 
effect on cardiac myocytes [45].  In addition, activation of these channels seems to occur 
as a response to decreased intracellular ATP levels, which is normally achieved within a 
few minutes after the onset of ischemia. Because KATP channels act as an inward rectifier 
[44] when activated, these effects could be caused by an increase of the depolarization 
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threshold that reduces excitation of either vascular smooth muscle or cardiac myocytes 
followed by vasodilation and shortening of the action potential duration, respectively, 
which finally lead to intracellular Ca2+ unloading [45] and, as a result, reduced metabolic 
demand. Since these phenomena resemble the acute cardiac responses and cardioprotection 
afforded by ischemic preconditioning, it has been postulated that KATP channels might be 
one of the critical effectors of both ischemic and pharmacological preconditioning [46]. 
Pharmacological preconditioning with KATP channel openers was first demonstrated in 
1992 [47], and it was thought to be an intervention downstream of the A1 adenosine 
receptor [48].  
An early study in 1991 [49] demonstrated that not only the cell membrane but also the 
inner mitochondrial membrane possessed ATP-sensitive inward rectifier activity, and 
therefore suggested the existence of "mitochondrial KATP channels" as opposed to 
"sarcolemmal KATP channels". After a long conception that both Ca2+ unloading and 
preservation of ATP were related to sarcolemmal KATP channels, it was found that both 
processes are actually mediated by mitochondrial KATP channels [50]. As a result, 
numerous studies on the cardioprotective effect of mitoKATP channel opening have been 
conducted, including many from our laboratory demonstrating the role of mitoKATP 
channel-opening in acute as well as delayed PC using several pharmacological agents. 
Unfortunately, despite all the positive results of PC associated with the opening of these 
channels, these so called "mitochondrial KATP channels" have still not been cloned after 
more than 10 years of investigation in spite of dramatic progress in the cloning of many 
mitochondrial proteins. Additionally, although some in vitro studies have shown a potent 
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effect of putative modulators of mitochondrial KATP channels [51] (diazoxide as an 
opener of KATP channels and 5-hydroxydecanoate (5-HD) as an inhibitor which are 
almost the only tools available to test the function of these channels), both drugs also have 
other important direct effects on cellular respiratory metabolism. Some recent studies using 
other models have failed to show complete modulation of the cardioprotective effect of 
ischemic preconditioning by these two drugs [52 and 53]. However, Pain et al. [54] have 
reported that reactive oxygen species (ROS), which are transiently generated by opening of 
the mitochondrial KATP channels, activate downstream cascades that confer 
cardioprotection. It is not clear why these differences exist, but some investigators 
focusing on mitochondrial KATP channels have suggested that the contribution of 
sarcolemmal KATP channels to cardioprotection may be more important in the beating 
hearts and less important under nonbeating experimental conditions (i.e., in vitro). 
Although many ongoing studies are providing some possible features or characteristics of 
mitochondrial KATP channels, the actual cardioprotective role of these channels needs to 
be investigated further in order to establish the cause-and-effect relationship between 
mitoKATP channel-opening and cardioprotection with PC. 
 
p38MAPK or PI3-K and their downstream cascades 
 There are over 1500 protein kinases identified so far among all different subclasses. 
Their main function is to transfer a terminal phosphate group from ATP or GTP to an 
amino acid (AA) residue; serine, threonine, or tyrosine. Different groups involve protein 
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kinases that specifically phosphorylate serine or threonine, referred to as ser/thr protein 
kinases, or tyrosine protein kinases that would specifically phosphorylate tyrosine. Another 
group of protein kinases that phosphorylates all 3 AA’s is a family known as mitogen 
activated protein kinases (MAPK). This family is yet the least understood. The major role 
that these protein kinases play is intracellular. When cells receive external signals initiated 
by several factors such as growth factors, cytokines, pharmacological agents or stress, 
intracellular pathways are activated which rapidly alter patterns of gene expression. This is 
the essence of cell signaling and the resulting cellular response to various types of stimuli. 
A certain extracellular stimulus would potentially activate a specific receptor at the level of 
the plasma membrane leading to the generation of second messengers within the cell. 
These chemicals and the extent to which they are expressed may alter the activity of 
certain protein kinases thus affecting the phosphorylation states of intracellular proteins 
and ultimately regulating their function. All these changes caused by the various signaling 
pathways eventually lead to specific physiological responses. 
Currently, there are four MAP kinase cascades that are differentially activated depending 
on stimulus type: the extracellular signal-regulated kinase/mitogen-activated protein kinase 
(ERK/MAPK) 1/2 pathway, the c-Jun amino-terminal kinase/stress-activated protein 
kinase (JNK/SAPK) pathway, the p38 pathway and the big mitogen-activated protein 
kinase BMK/ERK 5 pathway. Activation of the MAP kinase pathways leads ultimately to 
the phosphorylation of transcription factors bound to their regulatory elements in the 
promoters of target genes. Phosphorylation of these transcription factors is crucial for gene 
activation. The use of relatively specific MAP kinase and other inhibitors has allowed 
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elaborate investigation of the signaling pathways and/or mechanisms involved in 
phosphorylation of certain proteins in response to specific stimuli. The p38 pathway is 
inhibited by SB203580, which specifically binds to and inhibits p38 MAP kinase itself, 
rather than inhibiting its activation as in the case of some other MAPK’s.  
Within the past decade, it was proposed and demonstrated that several cellular stresses 
activated the p38 MAPK pathway. At least four isoforms of p38 were shown to exist, they 
are termed p38α, β, γ, and δ. There are also several protein kinases downstream of p38 that 
are activated following its phosphorylation. The role of p38 MAPK signaling in cellular 
responses is diverse, and has in fact given rise to controversy concerning its role in 
preconditioning of the myocardium depending on several factors such as cell type and 
stimulus. 
Despite the controversy concerning the physiological significance of p38 MAP kinase in 
the heart, it has been demonstrated that p38 is stimulated by I/R. Recent studies suggest 
that increased phosphorylation of p38 MAPK occurred in the preconditioned heart, which 
was completely abolished by SB203580, a selective inhibitor of p38 MAPK. It has also 
been demonstrated that increased p38 phosphorylation plays a pivotal role in several 
cardiac preconditioning approaches whether physiological or pharmacological in nature. 
As a result, the role of mitogen-activated protein kinases (MAPKs), which form part of the 
second messenger systems that mediate extracellular stimuli, in the cardioprotective effect 
of ischemic preconditioning has been further studied.  
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Not too long ago, a study in rabbits reported that ischemic preconditioning caused an 
increase of p38MAPK activation during sustained ischemia which was correlated with the 
cardioprotection provided by preconditioning [55]. However, p38MAPK was not activated 
during ischemia in the control group, while contradictory results were obtained a few years 
later by in vivo [56] and in vitro [57] studies that suggested p38MAPK activation could in 
fact promote ischemic damage. Treatment with anisomycin, a potent p38MAPK (and JNK) 
activator, just before ischemia could attenuate ischemic injury, with only the first peak of 
p38MAPK activation persisting and the second being abolished. This observation led to 
the hypothesis that p38MAPK activation has opposing effects; i.e., transient activation 
prevents ischemic injury, whereas continuous activation intensifies it.  
Furthermore, MAPKAPK-2 and HSP27 (one of the small heat shock proteins that acts as a 
molecular chaperone), which are downstream of p38MAPK, are activated in the 
preconditioned myocardium at the onset of sustained ischemia. Interestingly, MAPKAPK-
2 subsequently activates Akt, which lies downstream of PI3-K [58], to antagonize 
apoptotic signals. PI3-K can be activated by PC [59] and is also reported to cause an 
increase of nitric oxide (NO) production and the downstream activation of PKC [59]. On 
the other hand, HSP27 binds to the z-bands of myofibrils to prevent ischemic degradation 
of myofilaments [60] or prevents the interaction of Apaf-1 with procaspase-9 through 
binding with cytochrome c [61] which is released from the mitochondria and enhances this 
interaction [62].  
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Bradykinin and opioids 
Several studies have implicated bradykinin [63] as a candidate trigger for 
preconditioning. The cardioprotective effect of bradykinin has been intensively 
investigated [64], and it is known that preconditioned hearts show an increase of the 
interstitial bradykinin level [65]. The downstream effectors are reported to be an increase 
of nitric oxide production [66] or opening of KATP channels [67] after activation of the 
bradykinin B2 receptor.  
While bradykinin is considered to be an endogenous trigger of preconditioning, as 
mentioned above, activation of the δ-opioid receptor by opioid peptides has also been 
investigated as a potent exogenous trigger of preconditioning in isolated human cardiac 
tissue [68]. Many reports have suggested that KATP channels are the downstream 
mechanism of cardioprotection, but the relative contribution of either sarcolemmal [69] or 
mitochondrial [70] KATP channels to the triggering phase remains unclear. It has also 
been shown that by selectively activating the δ-opioid receptor with DPDPE, a selective 
agonist, the survival time in mice increased under hypoxic environments. Gross et al also 
demonstrated that ischemic PC is mediated by activation of the δ-opioid receptor, and by 
employing BNTX, the δ-opioid receptor antagonist, the infarct-limiting effect of PC was 
abolished. 
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4. Late phase PC: Cellular mechanisms 
The late phase of preconditioning, which was initially reported as the "second window of 
preconditioning" [12 and 13] in 1993, occurs about 24 hr (the actual time varies among 
species and experimental models) after transient preconditioning and lasts for much longer 
than the early phase, up to 72 hr post PC. 
As previously described, the late phase of ischemic preconditioning has essentially 
different signaling mechanisms from the early phase (classical ischemic preconditioning) 
such that it involves processes that require a longer time to occur. Recent studies have 
revealed that these two types of preconditioning share some triggering mechanisms, while 
certain mediators and effectors are reported to be specific for the late phase of 
preconditioning. In this part of our discussion, we will focus on the various mediators or 
effectors involved in late preconditioning.  
Adenosine 
 The adenosine-triggered cardioprotection that appears after 24 to 72 h is reported to 
have some unique characteristics [14]. Adenosine-triggered cardioprotection involves both 
adenosine A1 and A3 receptors, and it only reduces the infarct size rather than having an 
influence on stunning or arrhythmias. Initial transient activation of adenosine A1 receptors 
causes activation of subcellular signaling pathways, such as p38MAPK or HSP27 [71], and 
increases the synthesis of manganese superoxide dismutase (Mn–SOD) [72], but the role of 
A3 receptors remains not fully understood.  
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Nitric oxide (NO) 
 Nitric oxide (NO) was first identified as endothelium-derived relaxation factor 
(EDRF). In the cardiovascular system, it was shown to quite a similar role to adenosine 
such as having negative inotropic effects, vasodilatory effects, and inhibition of cytokine 
production as well as platelet aggregation. All of these actions are mediated through cyclic 
GMP as a second messenger [73]. It has also been suggested that an increase of NO prior 
to sustained ischemia plays a part in either ischemic or pharmacological preconditioning 
[74], indicating that NO could act as either a trigger or an effector of preconditioning 
which also resembles the role of adenosine. Furthermore, in contrast with the established 
role of NO in the triggering of late phase cardioprotection, whether NO can trigger the 
early phase of cardioprotection remains controversial. NO is reported to share downstream 
pathways with various other triggers [such as acetylcholine (Ach), bradykinin, opioids, and 
phenylephrine), involving PKC, KATP channels, and the generation of reactive oxygen 
species (ROS) in the triggering phase, but its other downstream effects are unknown. Some 
studies [73] reported that PKC activates NF-кB after several hours which then causes 
increased expression of inducible NO synthase (iNOS) after 4 to 8 h.  
Although we have mentioned a direct cardioprotective effect of NO, it also forms 
peroxynitrite (ONOO−) and promptly loses its bioactivity as a stimulator of cyclic GMP in 
the presence of high levels of free radicals. It remains unclear whether peroxynitrite is 
beneficial or harmful to the myocardium because it has been reported to damage vascular 
endothelial cells [75], whereas another study showed that formation of ONOO− is required 
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for NO to act as a trigger of preconditioning [76]. So, in this respect, it is believed that the 
levels of NO produced are critical in terms of NO being harmful or beneficial. NO, in large 
amounts, is highly toxic for cells and eventually causes cell death. On the other hand, if 
“optimal” concentrations of NO were produced at the right time, NO would activate GC 
and lead to the formation of cGMP which in turn activates PKG and results in 
cardioprotection through opening of mitoKATP channels. In addition, accumulation of 
cGMP, especially in vascular smooth muscle cells, causes smooth muscle relaxation and 
hence vasodilation. This vasodilatory effect is believed to potentially cause the release of 
certain endogenous mediators of PC, such as adenosine, bradykinin and acetylcholine. 
Furthermore, some studies using mice with gene targeting have indicated that endothelial 
NOS (eNOS) is also responsible for cardioprotection [79]. Again, regardless what the 
source of NO is, whether it is nNOS, iNOS or eNOS, it could probably be concluded that 
the overall effect of NO, under optimal doses, on the cardiovascular system is beneficial, 
although the results might vary among species and experimental models.  
 
 
Heat shock proteins (HSPs) 
 Intensive research has been conducted to examine the role of HSPs in the 
cardioprotection induced by ischemic PC. It has been reported that the expression of 
HSP70/72, a high molecular weight heat shock protein, peaks at 24 to 48 h after 
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preconditioning ischemia [78]. The main known fuction of HSP 70/72 is its action as a 
molecular chaperone; however, its cardioprotective effect may be related to other factors 
induced by HSPs as previously described for HSP27. Inhibition of PKC, by chelerythrine, 
prior to preconditioning completely abrogated the induction of these HSPs [79], suggesting 
that PKC also mediates cardioprotection through the generation of HSPs.  
On the other hand, ischemic preconditioning also activates Mn–SOD, and the peak level is 
seen at 24 h after preconditioning [79]. Because increased expression of Mn–SOD has 
been detected in a model of HSP72 overexpression [78], it may also be sequentially 
involved in ischemic or heat stress-induced preconditioning. As a result, some studies were 
performed to test the effect of exogenous Mn–SOD [80], and they showed that this 
approach fails to protect the myocardium against ischemic damage or reperfusion injury. 
This suggests that free radicals may play different roles during the process of ischemia and 
reperfusion injury depending on the site of their generation, i.e., inside or outside cardiac 
myocytes.  
 
 
Arachidonic acid 
 The most recent studies on the downstream pathways have addressed 
cardioprotection mediated by the induction of enzymes in the arachidonic acid cascade, 
mainly cyclooxygenase-2 (COX-2) [81]. iNOS and its product NO may activate COX-2 in 
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the late phase of cardioprotection [82], but the contribution of its products is currently 
unknown. These findings are interesting with respect to possible links with further 
downstream internal mediators that are believed to be the final effectors of 
preconditioning, as well as the concept that the immune response may be a direct effector 
of the cardioprotection afforded by preconditioning, and are also encouraging with regard 
to clinical application.  
All the aforementioned mediators of PC are summarized in Figure 1 to illustrate their 
interaction at the subcellular level in order to bring about the whole concept of myocardial 
PC. 
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Figure 1 
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5. Pharmacological PC 
 After having discussed many of the mechanisms identified thus far in ischemic PC, 
and after mentioning more than once that inducing brief episodes of ischemia is not a 
practical approach for management of patients with cardiovascular disease, we finally 
reach the major goal behind all these studies. Scientists in this field always desired to 
devise or discover chemicals or pharmacological agents that are able to target one or more 
of the signaling molecules implicated in ischemic PC in order to achieve similar 
cardioprotective results bypassing the ischemic stimulus. So far, among the many 
candidates suggested by experimental studies, there are two agents that have also been 
shown to minimize damage due to reperfusion injury in the clinical setting: adenosine and 
the KATP channel opener nicorandil.  
 
 
Adenosine 
 In a clinical trial [83], patients with acute anterior myocardial infarction who 
underwent continuous intravenous infusion of adenosine together with PTCR had smaller 
infarcts and better functional recovery than those without adenosine infusion. In this study; 
however, no cardiac function data were correlate with the observed reduction in infarct 
size. Therefore, more studies should be conducted in order to better evaluate the effect of 
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adenosine or ATP administration in the clinical setting not only on infarct size reduction, 
but also functional recovery by employing angiography. 
 
KATP channel openers 
 Some experimental [84] and clinical trials using either intravenous [85] or 
intracoronary [86] administration have shown that the no-reflow phenomenon following 
reperfusion can be prevented after successful PTCA, together with a reduced infarct size 
and better recovery from hypokinesis, by continuous infusion of a KATP channel opener 
(nicorandil) just after the procedure. Eventhough the no-reflow phenomenon has been 
proposed to be caused by arterial vasospasm [104], the exact mechanism by which 
nicorandil improves it remains unclear. Furthermore, the component of the KATP channel 
(mitochondrial or sarcolemmal) involved in this action of nicorandil is also controversial 
because many reports have confirmed that nicorandil has a stronger effect (10- to 100-fold) 
on the mitochondrial KATP channel than on the sarcolemmal KATP channel in vitro [87].  
Over the past 30 years, enormous progress has been made in our understanding of the basic 
biochemical and molecular mechanisms that underlie the development of lethal ischemia-
reperfusion injury and the protective actions of therapeutic interventions.   While 
adenosine is known to cause preconditioning and protection of the heart under these 
circumstances, it has been determined that the clinical effects are not as promising as those 
initially reported by experimental studies.  Over 3 years ago, we undertook a series of 
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novel investigations to determine the role of phosphodiesterase-5 (PDE-5) inhibitors in 
cardioprotection.These drugs are a novel class of vasoactive agents that have been 
developed for treatment of erectile dysfunction in men. Their mechanism of action 
involves active inhibition of PDE-5 enzyme resulting in accumulation of guanosine 
monophosphate (cGMP) levels and smooth muscle relaxation in the penis. Our initial 
hypothesis was that the vasodilatory action of these drugs may cause the release of certain 
endogenous compounds implicated in PC, such as adenosine, bradykinin, or acetylcholine. 
These mediators could potentially trigger signaling pathways leading to cardioprotection. 
Based on the intriguing hypothesis, we designed and performed the following 
investigations: 
Aim #1) to investigate whether sildenafil could confer cardioprotection against I/R injury 
in a manner similar to ischemic PC in the rabbit model of regional myocardial infarction;  
Aim #2) to demonstrate the behaviour of PKC isozymes after sildenafil treatment and their 
respective roles in cardioprotection with sildenafil in an in vivo rabbit model;  
Aim #3) To show that sildenafil could confer PC-like effects not only in the adult rabbit 
model, but also in infant rabbits;  
Aim #4) to examine the role of iNOS/eNOS proteins in the infarct-limiting effect of 
sildenafil in a mouse model of global I/R;  
Aim #5) to elucidate the signaling pathways involving activation of p38/ERK with 
sildenafil in an isolated mouse heart model;  
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Aim #6) to test the hypothesis that the adenosine A1 receptor plays a role in 
cardioprotection with sildenafil using A1 receptor knock-out mice. 
 
Aims 1 to 4 represent published papers in peer reviewed journals. The work on Aims 5 and 
6 has been completed and will be submitted for publication in the near future. 
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Summary:  Sildenafil citrate (Viagra) is the pharmacologic agent used for treatment of 
erectile dysfunction in men.  Since this drug has vasodilatory effect, we hypothesized that 
such an action may induce preconditioning-like cardioprotective effect via opening of 
mitoKATP channels.  Rabbits were treated with sildenafil citrate (0.7 mg/kg, iv) either 30 
min (acute phase) or 24 hrs (delayed phase) prior to 30 min of ischemia and 3 hrs of 
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reperfusion.  MitoKATP channel blocker, 5-hydroxydecanoate (5-HD, 5 mg/kg, iv) was 
given 10 min before ischemia/reperfusion.  Infarct size was measured by tetrazolium 
staining.  Sildenafil caused reduction in arterial blood pressure within 2 minutes of 
treatment, which returned to nearly baseline levels 3 minutes later.  The infarct size (% of 
risk area, mean±SE) reduced from 33.8±1.7 in control rabbits to 10.8±0.9 during acute 
phase (68% reduction, p< 0.05) and 19.9±2.0 during delayed phase (41% reduction, p< 
0.05). Similar acute and delayed cardioprotective effect was observed when sildenafil was 
administered orally. Systemic hemodynamics also decreased after oral administration of 
the drug. However, these changes were mild and occurred slowly. 5-HD abolished 
protection with increase in infarct size to 35.6±0.4 and 36.8± 1.6 during acute and delayed 
phase respectively (p<0.05).  For the first time, we demonstrate that sildenafil induces 
acute and delayed protective effect against ischemia/reperfusion injury which is mediated 
by opening of mitoKATP channels.   
 
Keywords: KATP channel, viagra, ischemia/reperfusion, infarction 
 
INTRODUCTION 
Sildenafil citrate (Viagra) is the first oral agent approved for treatment of erectile 
dysfunction in men (5,11).  It is a selective inhibitor of phosphodiesterase-5 (PDE-5), an 
enzyme that catalyzes the breakdown of a potent smooth muscle relaxing agent cyclic 
guanosine monophosphate (cGMP).  Sildenfil has been shown to enhance nitric oxide 
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(NO)-driven cGMP accumulation in the corpus cavernosum of rabbits without affecting 
cAMP formation.  In the absence of NO drive, sildenafil had no functional effect on the 
human and rabbit isolated corpus cavernosum, but potentiated the relaxant effects of NO 
on these tissues (20).  Also, it has been shown that sildenafil causes mild to moderate 
decreases in systolic and diastolic pressure because of the inhibition of PDE-5 in smooth 
muscles in the vascular bed (12).   In the present studies, we hypothesized that such a mild 
vasodilatory effect of the sildenafil in coronary vasculature could potentially release agents 
such as adenosine, bradykinin or NO that may trigger preconditioning-like effect in the 
heart.  Since opening of the mitochondrial KATP (mitoKATP) channel mediates the 
cardioprotective effect of preconditioning induced by adenosine (1,2,4,6) or sublethal 
ischemia (3), we further hypothesized that these channels could potentially be involved in 
the cardioprotective effect of sildenafil.   Accordingly, the goals of the present study were: 
(a) to show that the sildenafil induces both acute and delayed protection against 
ischemia/reperfusion injury in vivo and (b) to demonstrate if the protective effect of this 
drug is blocked by 5-hydroxydecanoate (5-HD), a selective blocker of mitoKATP channel 
(14). Using our in situ rabbit model of myocardial infarction, for the first time, we 
demonstrate that sildenafil induced both acute and delayed cardioprotective effects, which 
is dependent on the opening of mitoKATP channel.   
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MATERIALS AND METHODS 
Animals  
 
Male New Zealand White rabbits (2.8 to 3.3 kg) were used for the studies. The care and 
use of the animals were conducted in accordance with the guidelines of the Committee on 
Animals of Virginia Commonwealth University and the National Institute of Health (NIH) 
“Guide for the Care and Use of Laboratory Animals” [DHHS Publication No. (NIH) 80-
23, Revised, Office of Science and Health Reports, Bethesda, MD 20205]. 
 
Surgical procedure: Infarction protocol 
 
The rabbits were anesthesized with an intramuscular injection of ketamine HCl (35 mg/kg) 
and xylazine (5 mg/kg).  Subsequent doses of ketamine-xylazine (10 mg/kg and 2 mg/kg, 
respectively) were administered during the experiment as needed to maintain surgical 
anesthesia. Atropine was administered along with the anesthetic in order to keep the heart 
rate elevated especially during the surgery protocol.  The body temperature was monitored 
and maintained at 38°C throughout the experimental protocol.  The neck was opened with 
a ventral midline incision and tracheotomy performed followed by intubation.  The animal 
was then mechanically ventilated on a positive pressure ventilator using compressed room 
air at 30-35 cycles/min with a tidal volume of approximately 15 ml.  Ventilator setting and 
pO2 were adjusted as needed to maintain the arterial blood gas parameters within the 
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physiological range. The blood gases and pH were measured 12 times for all the groups 
during the infarction protocol. The arterial blood gases and pH values ranged between 7.20 
and 7.50 with pCO2 maintained between 20 and 50 mmHg and the HCO3 level ranging 
between 15.0 and 28.0 mg/L.  The pO2 ranged between 60 and 150 mmHg with the 
saturation constantly kept above 90%.   The jugular vein was cannulated with a 
polyethylene (PE) catheter for continuous infusion of 0.9 % saline solution.  The carotid 
artery likewise was dissected and cannulated with a PE catheter for blood sampling and 
continuous arterial pressure monitoring.  Electrocardiographic leads were attached to 
subcutaneous electrodes to monitor either limb lead II or lead III. 
Following stabilization of the hemodynamics, a left thoracotomy was performed through 
the fourth intercostal space and the pericardium opened to expose the heart.  A 5-0 silk 
suture with atraumatic needle was then passed around the left anterior descending artery 
(LAD) midway between the atrioventricular groove and the apex.  The ends of the tie were 
then threaded through a small vinyl tube to form a snare.  To induce infarction, the LAD 
was occluded for 30 min by pulling the snare and then fixing it in place by clamping the 
vinyl tube with a hemostat.  A bolus of heparin sodium 500 IU was given immediately 
before coronary occlusion for prophylaxis against thrombus formation around the snare.  
Myocardial ischemia was confirmed visually in situ by regional cyanosis, ST 
elevation/depression or T wave inversion on electrocardiogram, hypokinetic/dyskinetic 
movement of the myocardium, and relative hypotension.  After 30 min of ischemia, the 
snare was released and the heart was allowed to reperfuse for 180 min.  This was readily 
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confirmed by hyperemia over the surface of the previously ischemic-cyanotic segment. The 
thoracic cavity was covered with the saline-soaked gauze to prevent the heart from drying.  
 
Measurement of Infarct Size 
 
Following completion of ischemia/reperfusion protocol, 500 units of heparin was injected 
and the heart was removed quickly and mounted on a Langendorff apparatus.  The 
coronary arteries were perfused with 0.9% saline containing 2.5 mM CaCl2.  After the 
blood was washed out, the ligation around the coronary artery was re-tightened and 
approximately 2 ml of 10 % Evan’s blue dye injected as a bolus into the aorta until most of 
the heart turned blue.  The hearts were then perfused with saline to washout the excess 
Evan’s blue, removed from the Langendorff apparatus, frozen and cut into 4 to 6 transverse 
slices from apex to base of equal thickness (≈1 mm).  The slices were then incubated in 1 
% TTC solution in isotonic pH 7.4 phosphate buffer at 370C for 20 minutes. TTC reacts 
with NADH in the presence of dehydrogenase enzymes causing the cells viable to stain 
with a deep red color. Red-stained viable tissue was easily distinguished from the infarcted 
gray or white-unstained necrotic tissue.  The slices were subsequently fixed in 10 % 
formalin solution.  The area at risk was determined by negative staining with Evan’s blue.  
The areas of infarcted tissue, the risk zone, and the whole left ventricle (LV) were 
measured by computer morphometry using a Bioquant imaging software (BIO98).  Infarct 
size was expressed both as a percentage of the ischemic risk area. 
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Measurement of hemodynamics 
 
Hemodynamic measurements included heart rate and mean arterial pressure, systolic and 
diastolic blood pressure.  Rate-pressure product was calculated as the product of heart rate 
and peak arterial pressure.   
 
 
 
Study Protocol 
 
All animals were subjected to infarction protocol consisting of 30 minutes of sustained 
ischemia by occlusion of coronary artery followed by 180 minutes of reperfusion. The 
effect of sildenafil was studied in the absence or presence of 5-HD in two phases i.e., the 
acute and delayed phase. In the acute phase, myocardial infarction protocol was carried out 
30 min after treatment with sildenafil.  In the delayed phase, ischemia/reperfusion protocol 
was carried out 24 hours later. The rabbits were randomly assigned into one of the 
following groups.    Following is the description of the experimental groups:  
 
Group I: (saline control, n=10): Rabbits received 0.9 % saline; Group II:  (Sildenafil, 
acute phase, n=6): The Viagra tablets were crushed and 0.7 mg/kg sildenafil was 
dissolved in 3 ml saline.  This preparation was given as IV bolus, approximating on a 
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mg/kg basis, the clinical dose of 50 mg administered to a 70 kg patient as described by 
Przyklenk and Kloner (15).   The animals were subjected to ischemia/reperfusion 30 
minutes later. Group III: (Sildenafil, delayed phase, n=6).  Animals were treated with 
sildenafil as in group II and subjected to ischemia/reperfusion 24 hrs later; Group IV:  
(5HD, n=7).  Control rabbits treated with 5-HD (5 mg/kg, IV) 10 min prior to sustained 
ischemia and reperfusion; Group V:  (Sildenafil, + 5HD, acute phase, n=6 ).  Sildenafil 
treated rabbits as in group II were given 5-HD (5 mg/kg, IV) 10 min prior to ischemia and 
reperfusion; Group VI:  (Sildenafil, + 5HD, delayed phase, n=6).  Sildenafil treated 
rabbits as in group III were given 5-HD (5 mg/kg, IV) 10 min prior to ischemia and 
reperfusion.   
 
In addition, a subset of three groups of animals (n=5-6 per group) were given sildenafil 
citrate orally (1.4 mg/kg) or saline (control) in order to determine the early and delayed 
cardioprotective effect of the drug through this route.  Since there is 40 % bioavailability of 
sildenafil citrate after oral administration (http://www.pfizer.com/hml/pi's/viagrapi.pdf), 
we used double the dose of intravenous route i.e., 1.4 mg/kg which is equivalent to clinical 
dose of 100 mg for a 70 kg patient.   
 
Statistics 
 
All measurements of infarct size and risk areas are expressed as group means ± SEM.  
Changes in hemodynamics and infarct size variables were analyzed by a two-way repeated 
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measure ANOVA to determine the main effect of time, group and time by group 
interaction.  If the global tests showed major interactions, post hoc contrasts between 
different time-points within the same group or between different groups were performed 
using t- test. Statistical differences were considered significant if p value was less than 
0.05.  
 
RESULTS 
 
Hemodynamics:  Intravenous administration of sildenafil citrate (0.7 mg/kg) caused rapid 
decrease in hemodynamcs as indicated by 24.5 %, 47.3 % and 38.8 % decline in systolic, 
diastolic and mean arterial pressure respectively within 2 minutes (Figure 1A).  The 
systemic hemodynamics returned to nearly baseline levels by 5 minutes after treatment 
with sildenafil.  No significant changes in heart rate were observed following treatment 
with sildenafil (not shown).   The effect of orally administered sildenafil citrate on 
systemic hemodynamics was milder and slower as compared to the intravenous dose of the 
drug.    The orally administered sildenafil caused approximately 9.2 %, 12.5 % and 10.3 % 
decrease in systolic, diastolic and mean arterial pressure respectively after 30 minutes of 
treatment with the drug (Figure 1B).   This hypotensive response remained significant even 
at 60 minutes after oral administration of drug.   No changes in heart rate were observed.   
Also, no significant changes in systemic hemodynamics were observed in control animals 
given saline orally (data not shown). 
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The heart rate, mean arterial pressure and rate pressure product during baseline, 
preischemia, 30 min of ischemia and 180 min of reperfusion period are shown in Table 1 
and 2.  The hemodynamics remained reasonably stable, although they gradually decreased 
in all the groups during experimental protocol.  Except at the indicated time points, the 
mean values were not significantly different between the groups at any time point.     
 
 
 
Infarct size 
 
The infarct size (% of risk area) reduced from 33.8 ± 1.7 in the saline treated control group 
to 10.8 ± 0.9 during acute phase  (68 %  reduction,  mean±SE, p< 0.05) and 19.9 ± 2.0 
during delayed phase (41 % reduction) in the sildenafil-treated rabbits (Figure 2A).  A 
similar reduction in infarct size was observed acutely (after 60 min) and 24 hrs later when 
sildenafil was administered orally (Figure B).  The infarct-limiting effect of sildenafil was 
abolished in animals treated with 5-HD as shown by significant increase in infarct size to 
35.6 ± 0.4 during acute phase and 36.8± 1.6 in the delayed phase (p<0.05 versus groups II 
and III treated with sildenafil, Figure 2A).  Control animals treated with 5-HD had an 
infarct size of 33.5 ± 1.9 which was not different from infarct size of 33.8 ± 1.7 in the 
saline controls (P>0.05).  A similar trend in the changes in infarct size was observed when 
expressed as a percentage of the left ventricle (not shown).  Similarly, the risk areas 
expressed as percentage of left ventricle were not statistically significant different between 
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the groups.  These data suggest that changes in the infarct size observed among various 
groups were not related to the percentage of the area of the left ventricle that was occluded 
by our technique.  Representative sections of the heart treated with sildenafil citrate 
intravenously clearly demonstrated significantly larger area of viable tissue (brick red 
color) as compared to saline treated control and sildenafil+5-HD treated animals, which 
had much larger gray and white areas in the risk zone (Figure 3). 
 
 
DISCUSSION 
 
Sildenafil citrate (Viagra) is currently the only approved oral drug for treatment of erectile 
dysfunction in men.  However, little is known about other beneficial effects of this drug.  
We report here our novel observation about the preconditioning-like effect of sildenafil in 
the adult rabbit heart.  Our results show that intravenous administration of sildenafil 
induces acute (early) and delayed cardioprotective effect as indicated by significant 
reduction in the infarct size when compared to the saline-treated controls.  Since the drug is 
taken orally by patients,  we further showed that feeding the rabbits with sildenafil citrate 
reduced infarct size acutely (after 1 hr) as well as 24 hrs later which was comparable to the 
infarct size reduction obtained by intraveous administration of the drug. The selective 
blocker of mitoKATP channels, 5-HD, when administered before the ischemia/reperfusion 
protocol, abolished both the early as well as delayed cardioprotection induced by sildenafil 
citrate.  Intravenous administration of sildenafil citrate caused severe transient decrease in 
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the systemic hemodynamics (diastolic, systolic and mean arterial blood pressure) within 2 
minutes after treatment returned to nearly baseline levels after 3 minutes.  Although a 
significant decrease in systemic hemodynamics was also observed after oral administration 
of the drug, these changes were mild and occurred slowly. The hemodynamics remained 
largely unchanged among the groups during ischemia/reperfusion protocol.  To our 
knowledge, this is the first study demonstrating (a) the direct cardioprotective effect of 
sildenafil in vivo and (b) the involvement of mitoKATP channel in mediating this protection 
in the ischemic heart. 
 
Sildenafil is a potent selective inhibitor of PDE-5 in vascular smooth muscle cells which is 
known to enhance erectile function in men (20).   Sexual stimulation results in the release 
of NO from nerves and endothelial cells in the corpus cavernosum of the penis that 
stimulates guanylate cyclase with subsequent formation of cGMP.    Accumulation of 
cGMP leads to smooth muscle cell relaxation in the arteries, arterioles and sinusoids in the 
corpus cavernosum that allow this erectile tissue to fill with blood and causing erection 
(10).  Men with erectile dysfunction may be unable to produce adequate amounts of cGMP 
because it may be broken down by PDE-5, which is found in high levels in the genitalia.  
Sildenafil inhibits PDE-5 allowing an increase in cGMP and improving vasodilation.  
Besides genitalia, PDE-5 is found in other vascular and visceral smooth muscles also (21).  
As a result, the administration of sildenafil causes vasodilation and decrease in the blood 
pressure.  We hypothesized that such a vasodilatory action of sildenafil could potentially 
release endogenous mediators of preconditioning such as adenosine, bradykinin or NO.  
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One or more of these mediators may trigger signaling cascade leading to opening of 
mitoKATP channel resulting in acute and delayed cardioprotective effect.  Indeed our results 
show a very impressive acute cardioprotective effect which is comparable or even better 
than ischemic preconditioning (28) and pharmacological preconditioning induced by 
activation of adenosine receptors, monophosphoryl lipid A or bradykinin (9,13,17,26,27).  
The  cardioprotective effect after 24 hrs  was  less  pronounced  during  delayed  phase i.e.,  
41% reduction in infarct size as compared to 67 % in the acute phase (% risk area), 
implying that there may be gradual waning of the sustained protective effect.  
Alternatively, it is possible that sildenafil-induced protection is biphasic, with acute and 
delayed phase protection controlled by separate mechanisms. 
 
 Another interesting observation in the present study is that both acute and delayed 
cardioprotective effects were blocked by 5-HD suggesting that opening of mitoKATP 
channels play an important role in the infarct size reduction by sildenafil in our model.  
Several studies have now conclusively demonstrated that opening of mitoKATP channels 
play an important role in ischemic as well as pharmacological preconditioning in the heart 
(7,8,18,22).  Mitochondria are known to play an essential role in cell survival by ATP 
synthesis and maintenance of Ca2+ homeostasis. Opening of the mitoKATP channel partially 
compensates the membrane potential, which enables additional protons to be pumped out 
to form a H+ electrochemical gradient for both ATP synthesis and Ca2+ transport (16). The 
acute protection induced by sildenafil may be mediated by opening of the mitoKATP 
channel either directly or through a variety of signaling pathways such as activation of 
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protein kinase C and MAP kinases.   The delayed phase could be through the signaling 
cascade leading to the synthesis of inducible nitric oxide synthase, generation of NO and 
opening of the mitoKATP channels as described previously (19,23,24,29-31).  Currently we 
do not have the evidence in support of this notion and further investigations are needed to 
determine the cellular and molecular mechanisms of cardioprotection by sildenafil.  
 
 
In the present studies, the sildenafil was given in normal rabbits with no sexual 
stimulation.  It has been suggested that sexual activity is comparable to moderate exercise, 
particularly in men with coronary artery disease who may have been physically inactive to 
engage in sexual activity (10).  Since exercise triggers preconditioning-like effect in animal 
models (25), it is possible that men taking sildenafil prior to sexual intercourse could 
potentially have additive cardioprotectve effect of moderate exercise.  On the other hand, 
concerns over the safe use of sildenafil in patients with ischemic heart disease have been 
raised.  While the overall safety of sildenafil use has been well established, the co-
administration of long and short-acting nitrate preparations has been associated with 
significant hypotension and adverse cardiovascular effects.  In addition, caution has been 
recommended in prescribing sildenafil to patients with unstable ischemic coronary 
syndromes, severe LV dysfunction, or patients who are on multiple-drug antihypertensive 
regimens (5, 12).  Therefore, careful clinical studies are required to evaluate the 
preconditioning-like effect of sildenafil in patients with ischemic heart disease.    
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In conclusion, for the first time, we have demonstrated that intravenous or oral 
admininstration of sildenafil citrate induces significant cardioprotective effect against 
ischemia/reperfusion injury, the impact of which was powerful within 30 minutes and 
persisted to slightly lesser degree 24 hrs after administration of the drug.  The extent of 
protection observed with sildenafil was comparable to preconditioning induced by 
sublethal ischemia and several other pharmacological agents.  Furthermore, our results 
show that the cardioprotective effect of sildenafil was mediated by opening of mitoKATP 
channel, a proposed end-effector of myocardial preconditioning (8,22).  Further 
investigations are needed to understand the molecular mechanism(s) of sildenafil-induced 
cardioprotective effect which would help in expanding the utility of this drug for other 
cardiovascular diseases in addition to the current use for treatment of erectile dysfunction 
in men.  
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Figure Legends 
 
Figure 1:  Changes in hemodynamics following administration of sildenafil 
intravenously (A) or orally (B) administration of sildenafil citrate.  SBP – systolic 
blood pressure, DBP – diastolic blood pressure; MAP – mean arterial blood pressure. 
Results are means±SE from 6-7 rabbits. 
 
Figure 2:  A.  Bar diagram showing infarct size (% risk area) after intravenous 
administration of  sildenafil citrate.  Saline control - Animals receiving 0.9 % saline; 
Sildenafil (acute phase) - Rabbits receiving sildenafil (0.7 mg/kg, IV) 30 min prior to 
ischemia/reperfusion; Sildenafil (delayed phase): animals receiving sildenafil (0.7 mg/kg, 
IV) 24 hrs prior to ischemia/reperfusion.   5-HD – Control (saline-treated) rabbits received 
5-HD (5 mg/kg) 10 min prior to sustained ischemia and reperfusion. Sildenafil+5-HD 
(acute phase): Sildenafil treated rabbits given 5-HD (5 mg/kg, IV) 10 minutes prior to 
sustained ischemia and reperfusion.  Sildenafil+5-HD (delayed phase):  Rabbits treated 
with sildenafil 24 hrs prior to ischemia/reperfusion were given 5-HD.  Results are 
means±SEM in 6-7 rabbits in each group.  *P < 0.05 compared to control, sildenafil, 
sildenafil + 5-HD (acute and delayed), and 5-HD groups. 
B.  Reduction of infarct size (% of risk area) after oral administration of sildenafil 
citrate.  Rabbits were given sildenafil (1.4 mg/kg) or equivalent volume of saline prior to 
ischemia/reperfusion protocol which was carried out after 60 min (acute phase) and 24 hrs 
later (for delayed phase).  
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Figure 3:  Representative sections of the heart demonstrating reduction of post-
ischemic infarct size 30 minutes following treatment with sildenafil and blockade of 
protective effect with 5-HD.  At the end of experimental protocol as described in 
Methods, the hearts were perfused with Evan’s blue to demarcate the risk area.   Each heart 
was then sliced into 4-5 sections and stained with TTC followed by fixation in formalin.  
The blue areas represent normal perfused tissue.  The viable areas are stained brick red 
whereas infracted are gray or white.  Note that significant viable area in the sections of the 
heart treated with sildenafil as compared to saline control or salidenafil + 5-HD treated 
rabbit.  Similar pattern was observed in the sections of the heart from delayed phase groups 
(not shown). 
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Figure 3 
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Abstract 
Sildenafil citrate (Viagra) is the most widely used drug for treating erectile 
dysfunction in men.  We recently demonstrated that it induces potent protective effects 
against ischemia-reperfusion (I-R) injury in rabbit hearts through opening of mitochondrial 
KATP channels.  In the present study, we investigated the role of nitric oxide (NO)-
dependent signaling pathway in delayed cardioprotection by sildenafil.  Adult male ICR 
mice were treated with Saline or Sildenafil (0.7 mg/kg, i.p.) 24 hours before global I-R in 
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Langendorff mode.  Infarct size was reduced from 27.6±3.3% in saline controls to 
6.9±1.2% in sildenafil-treated mice (means±SEM, P<0.05) without compromising cardiac 
function.  RT-PCR revealed a transient increase in endothelial and inducible NO synthases 
(eNOS and iNOS) mRNA in sildenafil-treated mice, peaking at 45 min (eNOS) and 2 
hours (iNOS) after sildenafil injection.  The magnitude of mRNA increase was more 
pronounced for iNOS than eNOS.  In addition, a significant increase in both iNOS and 
eNOS protein was detected 24 hours after sildenafil treatment.  Selective inhibitor of 
iNOS, 1400W (10 mg/kg, i.p. given 30 min before I-R) abolished sildenafil-induced 
protection (23.7±2.8%, P<0.05 vs. Sildenafil).  These data suggest that induction of NOS 
isoforms is an essential component of signaling mechanism for sildenafil-induced delayed 
preconditioning.  However, iNOS appears to be the primary isoform that mediates the 
robust cardioprotection. 
 
Introduction 
 
Sildenafil citrate (Viagra) is a selective inhibitor of phosphodiesterase-5 (PDE-5) that 
catalyzes the breakdown of cGMP – one of the primary factors involved in smooth muscle 
relaxation.  It enhances nitric oxide (NO)-driven cGMP accumulation which in turn causes 
vasodilatation in corpus cavernosum.  Sildenafil has become the most widely used drug for 
treating erectile dysfunction (ED) in men since its market debut in 1998.1 Interestingly, we 
recently discovered a powerful preconditioning-like effect of sildenafil in rabbit hearts.2  
Both intravenous and oral administration of sildenafil caused significant reduction of 
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infarct size following ischemia/reperfusion.  The protection was abolished by 5-
hydroxydecanoate, a selective blocker of mitoKATP channels.2 However, the mechanism by 
which sildenafil triggers signaling cascade leading to opening of mitoKATP remains 
speculative2.  There is mounting evidence suggesting a role of NO in modulating mitoKATP 
.3-6  The synthesis of NO is catalyzed by three isoforms of NO synthase, namely, neuronal 
(nNOS), inducible (iNOS), and endothelial (eNOS), among which iNOS has been 
identified as the essential mediator of delayed preconditioning induced by divergent 
pathophysiological stimuli or pharmacological agents, such as brief episodes of ischemia-
reperfusion (I-R),7 endotoxin derivatives,8,9 G protein-coupled membrane receptor 
agonists,10,11 whole body hyperthermia,12 and systemic hypoxia.13  However, no studies are 
available showing any link between sildenafil and activation of NOS-dependent signaling 
cascade.  The goal of the present report was to show if: 1) sildenafil induces synthesis of 
NOS isoforms in the heart and, 2) iNOS mediates the delayed preconditioning effect in the 
mouse heart.  
 
Materials and Methods 
 
 
Physiological Studies.  Adult male out-bred ICR mice were supplied by Harlan.  
Animal experiment protocols were approved by the Institutional Animal Care and Use 
Committee of Virginia Commonwealth University.  Viagra pills (Pfizer Inc.) were ground 
into powder and dissolved in saline.  The drug solution was filtered (0.45 µm pore size) 
before intraperitoneal (i.p) injection.  iNOS inhibitor – 1400W was obtained from Alexis.  
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We used Langendorff isolated perfused mouse heart model subjected to 30 min of global 
ischemia and 30 min of reperfusion.  Myocardial I-R injury was assessed by measuring 
infarct size, contractile function, and coronary flow as described previously.9 
Twenty eight mice were randomized into the following four groups (n = 6-9/group): 1) 
Saline (0.15 ml, i.p.);  2) Sildenafil (0.7 mg/kg, i.p., equivalent to 50 mg Viagra pill used 
for ED patients, given 24 hrs befre I-R);  3) Sildenafil+1400W (10 mg/kg, i.p.,14 given 30 
min prior to I-R); and 4) Saline+1400W. 
 
Measurement of NOS isoforms.  Mice were treated with sildenafil (0.7 mg/kg, i.p.), 
hearts were removed at 15 min, 30 min, 45 min and 1, 2, 3, 4, 24 hrs post injection (n = 
3/group).  Three non-treated hearts were used as controls.  Tissue samples were ground 
under liquid nitrogen and homogenized with TRI Reagent (Molecular Research Center) for 
extracting total RNA, which was reverse-transcribed into cDNA at 50 oC for 30 min using 
OneStep RT-PCR Kit from Qiagen.  The oligonucleotide primers were synthesized based 
on published sequences for murine iNOS, eNOS, and GAPDH.15 (Integrated DNA 
Technology).  The RT-PCR products were electrophoresed on 1.5% Tris-Acetate-EDTA 
agarose gel.  The target bands were identified based on their specific size using DNA 
standards.   
iNOS and eNOS proteins were measured by Western blots as described previously.13  
In brief, triplicate heart samples were collected 24 hours after saline or sildenafil injection 
and homogenized in ice-cold RIPA buffer (Upstate Biotechnology).  The homogenate was 
centrifuged at 10,000g for 10 min under 4°C, and supernatant was recovered as the total 
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cellular protein.  60 µg total protein from each sample was separated by SDS/PAGE on 
10% acrylamide gels and transferred to a PVDF membrane, and then blocked with 5% 
non-fat dry milk in TBS.  The membrane was subsequently incubated with a rabbit 
polyclonal antibody (Santa Cruz; dilution 1:500) reacting specifically to iNOS, eNOS, or 
actin.  The secondary antibody was a horseradish peroxidase-conjugated anti-rabbit IgG 
(Amersham, 1:1,000 dilution).  The membranes were developed using enhanced 
chemiluminescence and exposed to x-ray film. The mRNA and protein expression were 
quantified by scanning each of the RT-PCR or Western blot band using a densitometer 
(Bioquant 98). 
 
Data Analysis and Statistics.  Data are presented as means±SEM.  The difference 
among the treatment groups or the time points after sildenafil injection was compared by 
unpaired t test or one-way ANOVA followed by Student-Newman-Keuls post-hoc test.  
P<0.05 was considered significant. 
 
Results and Discussion 
 
Pretreatment of mice with sildenafil reduced infarct size 24 hrs later (6.9±1.2%), as 
compared to saline-treated controls (27.6±3.3%; P<0.05, Figure 1).  The infarct-limiting 
effect of sildenafil was not associated with compromised ventricular contractile function, i.e. 
stunning (Figure 1, Bottom panel), which is in agreement with the results of Przyklenk and 
Kloner.16  Sildenafil did not alter pre- or post-ischemic coronary flow (data not shown), 
indicating its cardioprotective effect may be independent of its vascular response 24 hrs later.  
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These results confirmed our previous findings showing a powerful cardioprotective effect 
of sildenafil in rabbit heart.2   There was increase in iNOS and eNOS mRNA and protein 
expression (Figure 2 and 3).  The levels of these transcripts increased transiently, peaking 
at 45 min (eNOS) and 2 hrs (iNOS) after sildenafil treatment and returning to baseline 
levels several hours later (Figure 2).  The magnitude of increase for iNOS was much higher 
compared with eNOS.  In addition, sildenafil-induced protection was abolished by selective 
iNOS inhibitor, 1400W (Infarct size, 23.7±2.8%, P<0.05 vs. Sildenafil).  1400W had no 
significant effect on infarct size as compared with saline-treated hearts (24.5±1.0%; P>0.05 
vs. Saline). 
Several studies have shown that NO derived from iNOS plays a major role in delayed 
cardioprotection induced by endotoxin derivatives,8,9 agonists of adenosine or adrenergic 
receptors,10,11 p38 activator,17 and mitoKATP opener – diazoxide.6   The role of sildenafil in 
stimulating the release of NO in heart is unknown.  We provide the first evidence that 
sildenafil is a potent inducer of iNOS mRNA and protein, which leads to delayed 
cardioprotection.  Although eNOS mRNA and protein also increased, their quantitative 
expression was lower than iNOS.  The role of eNOS is not clear in the present study.  The 
complete blockade of cardioprotection with 1400W given before ischemia rules out the 
role of eNOS in the mediator phase of delayed protection.  However, eNOS may play a 
role in the trigger phase, i.e. at the time of sildenafil treatment when NO from eNOS may 
initiate the signaling cascade leading to iNOS expression as proposed by Bolli and 
coworkers.18,19  The iNOS-catalyzed NO generation could potentially activate guanylate 
cyclase resulting in enhanced formation of cGMP.  cGMP may activate protein kinase G 
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(PKG) that can subsequently open mitochondrial KATP channel resulting in the 
cardioprotective effects as recently reported.20 
To conclude, for the first time, our results show that sildenafil induces delayed 
preconditioning which is primarily mediated by NO derived from iNOS.  Further studies 
are needed to understand the signaling mechanism(s) that lead to transcription and 
expression of eNOS and iNOS in the heart.  The current study in a model of global I-R 
further expands our knowledge on the cardioprotective effect of sildenafil, which may 
potentially be used for treatment of patients with ischemic heart diseases. 
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Legend of Figures 
 
Figure 1.   Effect of sildenafil and/or 1400W on myocardial infarct size (Top) and 
ventricular functional recovery (Bottom) following global ischemia-reperfusion. 
  
 Figure 2.  Time course of iNOS and eNOS mRNA expression determined with RT-
PCR following sildenafil treatment.  Top panel shows representative pictures of 3 
independent experiments.  The scatter plots present the densitometric results averaged from 
3 individual hearts for each time point, which were normalized against GAPDH level for 
each sample. 
 
Figure 3.  Cardiac expression of iNOS and eNOS protein 24 hrs after sildenafil 
treatment.  The bar graph shows the densitometric quantification averaged from 3 
individual hearts for each group, which is normalized against Actin level for each sample. 
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ABSTRACT 
 
Sildenafil citrate (Viagra) is the most widely used pharmacological drug for 
treating erectile dysfunction in men. It has potent cardioprotective effects against ischemia-
reperfusion (I/R) injury via nitric oxide and opening of mitoKATP channels. We further 
investigated the role of protein kinase C (PKC)-dependent signaling pathway in sildenafil-
induced cardioprotection. Rabbits were treated (orally) with sildenafil citrate (1.4 mg/kg, 
iv) 30 min prior to index ischemia for 30 min and reperfusion for 3 hrs. PKC inhibitor, 
chelerythrine (5 mg/kg, iv) was given 5 min prior to sildenafil.  Infarct size (% of risk area) 
reduced from 33.65 ±2.17 in vehicle (saline) group to 15.07±0.63 in sildenafil-treated 
groups, a 45 % reduction compared to the vehicle (mean ± SEM, p<0.05). Chelerythrine 
abolished sildenafil-induced protection as demonstrated by increase in infarct size to 
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31.14±2.4 (p<0.05).  Chelerythrine alone had an infarct size of 33.5±2.5, which was not 
significantly different when compared to DMSO treated group (36.8±1.7, P>0.05). 
Western blot analysis demonstrated translocation of PKC-α, -θ and -δ isoforms from 
cytosol to membrane after treatment with sildenafil.  However, no change in PKC-β and -ε 
isoforms was observed.  These data provide direct evidence of an essential role of PKC, 
and potentially PKC-α, -θ and -δ in sildenafil-induced cardioprotection in rabbit heart. 
 
Introduction 
 
Sildenafil Citrate (Viagra), a specific phosphodiesterase-5 (PDE-5) inhibitor 
currently approved for the treatment of erectile dysfunction in men, has been shown to 
acutely enhance endothelium-dependent vasodilation in patients with heart failure (7). This 
drug allows accumulation of the potent relaxing agent cGMP in vascular smooth muscle 
cells by preventing its breakdown by PDE-5.  Sildenafil has been shown to enhance nitric 
oxide (NO)-driven cGMP accumulation in the corpus cavernosum of rabbits without 
affecting cAMP formation (33). It causes mild to moderate decrease in systolic and 
diastolic pressure because of the inhibition of PDE-5 in smooth muscle cells in the 
vascular bed (13). Interestingly, our laboratory recently observed that sildenafil induced 
both acute and delayed cardioprotective effects against ischemia-reperfusion injury in 
rabbits which was dependent on the opening of mitochondrial ATP-sensitive potassium 
(mitoKATP) channel (23). In addition, we demonstrated that sildenafil induced delayed 
preconditioning in the mouse heart through increased expression of inducible nitric oxide 
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synthase (iNOS) (31). However, the signaling mechanism involved in cardioprotection is 
currently unknown. 
  Several studies suggest that protein kinase C (PKC) activation plays an important 
role in the mechanism of preconditioning (1, 2, 15, 17, 26, 37).  The PKC family of 
isozymes has three major subgroups: the conventional, calcium-dependent (α-, ßI-, ßII-, 
and γ), the novel, and calcium-independent PKC isozymes (δ-, ε-, η-, θ-, and possibly µ). 
Translocation of PKC isoform(s) from the cytosolic to the particulate fraction (including 
sarcolemmal, mitochondrial as well as nuclear fractions) result in their binding to specific 
receptors of activated C kinase (RACKs) localized in membranes (20, 21). Translocated 
specific PKC isoforms are believed to participate in several functions including the 
opening of mitoKATP channels or the induction of gene expression (9, 34, 35).  It has been 
shown that PKC-mediated cardioprotection is isoform specific: the ε and η-isoforms play 
an essential role in the development of ischemic preconditioning in rabbit myocardium (4, 
15, 16, 27, 29). In addition, a number of pharmacological agents cause cardioprotective 
effect through selective translocation of PKC isoforms to the membrane fractions (14, 32, 
40). However, the role of PKC or translocation of specific isoform(s) following sildenafil 
induced cardioprotection is not known.  Accordingly, the goal of the present investigation 
was (a) to show if the cardioprotective effects of sildenafil is blocked by the PKC inhibitor, 
chelerythrine in the rabbit heart and (b) to determine whether sildenafil induces 
translocation of specific isoform(s) of PKC from the cytosolic to the particulate fraction. 
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MATERIALS AND METHODS 
 
Experimental Protocol. All animals were subjected to an infarction protocol 
consisting of 30 min of sustained ischemia by occlusion of the coronary artery followed by 
180 min of reperfusion (Figure 1A). The effect of sildenafil was studied in the absence or 
presence of chelerythrine chloride. The myocardial infarction protocol was carried out 60 
min after treatment with sildenafil.  The rabbits were randomly assigned into one of the 
following groups. Group I: (saline control, n=6): Rabbits received 0.9 % saline; Group II:  
(Sildenafil, n=6): The Viagra tablets were crushed, dissolved in water and given orally to 
the rabbits. Because there is 40% bioavailability of sildenfil citrate after oral 
administration, we used double the dose of the intravenous route; i.e. 1.4 mg/ kg, which is 
equivalent to clinical dose of 100 mg for a 70-kg patient.  Our previous study (23) has 
shown that an oral dose of 1.4 mg/kg is as potent as the intravenous dose of 0.7 mg/kg in 
cardioprotection.  In addition, a group of animals were given sildenfil cytrate (0.7 mg/kg) 
as an IV bolus, the clinical dose of 50 mg administered to a 70 kg patient (28). Group III: 
(Sildenafil + Chelerythrine):  Chelerythrine chloride was dissolved in DMSO (25 
mg/2.5ml DMSO) and 5 mg/kg chelerythrine was administered 5 min prior to sildenafil 
treatment. Group IV: (Cheleryhtrine): Chelerythrine was given alone without sildenafil. 
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Group V (DMSO): DMSO, the solvent for chelerythrine, was administered 35 min prior to 
ischemia/reperfusion protocol.   
Surgical Preparation. The surgical protocol is identical to that discussed in  
Chapter 2. 
 
Measurement of Hemodynamics.  The method of measuring hemodynamics used in 
Chapter 2 was applied in this study. 
 
Measurement of subcellular distribution of PKC isozymes.   For measurement of 
PKC, rabbits were administered sildenafil (1.4 mg/kg) or saline orally and hearts were 
excised 30, 60 and 120 minutes later (Figure 1B). The left ventricle was dissected and 
stored in liquid nitrogen until used. The frozen tissue samples were ground in a pre-chilled 
mortar and pestle under liquid nitrogen. Total cellular proteins were obtained by glass-
glass homogenization of the powdered tissue in 3 ml extraction buffer containing 50 mM 
Tris-HCl (pH 7.5), 5 mM EDTA, 10 mM EGTA, 50µg/ml PMSF, protease inhibitor 
cocktail (10µl/ml, Sigma, product No. P8340), 0.3% β-mercaptoethanol as described by 
Qiu et al. (29). The homogenates were centrifuged at 45,000g for 30 min at 4oC. The 
supernatant containing cytosolic protein was saved, and the pellet was re-suspended in 3 
ml of same extraction buffer along with 1% (v/v) Triton X-100 and incubated on ice for 1 
hr and centrifuged at 45,000g for 30 min to obtain supernatant (particulate fraction). The 
protein concentration was determined using Bio-Rad Protein Assay kit (BioRad, Hercules, 
CA). 
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Cytosolic and membrane fractions (100 µg protein) were separated by SDS-PAGE 
on 10% denaturing acrylamide gels and transferred to nitrocellulose membranes. The blots 
were blocked with 5 % nonfat dry milk in TBST buffer (10 mM Tris-HCl, pH 7.4, 100 
mM NaCl and 0.1% Tween 20) for 1h. The blots were then incubated with 1,000 fold 
diluted primary antibodies against respective PKCs (Santa Cruz Biotechnology, California; 
cPKCα (SC-8393); cPKCβ1, (SC-8049); nPKCδ (SC 8402); nPKCε (SC-1681); nPKCθ 
(SC-1680) to assess the expression of individual PKC isoform. To normalize for loading of 
protein, we used ß-actin antibody (Sigma, A-2172). After 2 hrs of incubation with 
respective primary antibodies, the blots were washed and incubated with anti-mouse 
horseradish peroxidase-conjugated secondary antibody (1:2000 dilution, Amersham 
Pharmacia Biotech, UK) for 1hr. The blots were developed with the use of a 
chemiluminescent system (ECL kit, Amersham). Each immunoblotting experiment was 
repeated twice and the results were averaged. For quantifying the protein translocation, the 
optical density for each blot was scanned and analyzed with a densitometric system 
(Bioquant 98). 
 
RESULTS 
 
Infarct size. Figure 2A shows infarct size expressed as the percentage of risk area.  
Preconditioning with sildenafil resulted in a significant decrease in the infarct size from 
33.65±2.17 in the control (saline) group to 15.07±0.63 in the sildenafil treated rabbits, a 
45% reduction compared to the vehicle (mean ± SEM, p<0.05). The infarct size increased 
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significantly to 31.14±2.4, (p<0.05) with chelerythrine when given 5 minutes prior to 
sildenafil treatment. Chelerythrine alone had an infarct size of 33.5±2.5, which was not 
significantly different when compared to the DMSO (solvent of Chelerythrine) treated 
group (36.9±2.3). A similar trend in the changes in infarct size was observed when 
expressed as a percentage of the left ventricle (not shown). Similarly, the differences 
between the risk areas expressed as a percentage of the left ventricle were not statistically 
significant between the groups (Figure 2B). These data suggest that changes in the infarct 
size observed among various groups were not related to the percentage of the area of the 
left ventricle that was occluded by our technique.  The infarct size (% of risk area) was 
reduced by 68% when sildenafil was administered intravenously (from 33.8 ± 1.7 in the 
saline-treated control group to 10.8 ± 0.9 in the sildenafil treated rabbits). This infarct size 
reduction was blocked by chelerythrine. 
 
Hemodynamics. The heart rate, MAP and RPP are shown in Table 1. The heart rate, 
MAP and RPP remained reasonably stable throughout the experimental period, although 
they gradually decreased in most of the groups.  Except at the indicated time points, the 
mean values were not significantly different between the groups at any time point within 
the groups. 
 
Translocation of PKC Isoforms.  We examined the sub-cellular distribution of five 
PKC isoforms (α, β1, δ, ε and θ) after 30, 60 and 120 min of oral administration of 
sildenafil by Western blot with the use of isoform-specific antibodies. As shown in Figure 
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3, PKC isoforms α, β1, δ, θ and ε isoforms were expressed in both cytosolic and membrane 
fractions. The subcellular distribution of these isoforms was generally higher in the cytosol 
as compared to the membrane fraction.  No significant change of the translocation of 
PKCα occurred from cytosol to membrane after 30 minutes of sildenafil treatment 
compared to control (saline treament) (Fig.3A). However, an increase in membrane PKCα 
was observed at 60 minutes, which reached significantly higher levels by 120 minutes of 
sildenafil administration.  PKCθ and δ exhibited significant increase of the translocation in 
the membrane fraction after 30 min to 120 min of sildenafil admistration  compared to 
control (Fig. 3B, C). Quantitative analysis showed increase of PKCα/β-actin ratio in the 
membrane fraction by sildenafil from 0.52±0.06 (in control) to 0.70±0.04 after 120 min 
(p<0.05) (Fig.3A). The ratio of PKCθ/β-actin in the membrane fraction increased from 
0.62±0.06 in saline control to 0.87±0.08 (p<0.05) after 120 min of sildenafil treatment 
(Figure 3B). Similarly, PKCδ/β-actin ratio in the membrane fraction increased from 
0.74±0.06 (control) to 0.94±0.03 (sildenafil) (p<0.05) by 120 min of sildenafil treatment 
(Fig. 3C). In contrast no significant increase of translocation of PKCβ (Fig. 3D) and ε (Fig 
3E) to membrane occurred following sildenafil treatment.  
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DISCUSSION 
 
The use of sildenafil for treatment of erectile dysfunction by many patients with 
cardiovascular disease has resulted in a tremendous interest in the cardiovascular 
properties of the drug (3). Recently we reported that administration of sildenfil induced 
cardioprotection as indicated by significant reduction in the infarct size when compared to 
the controls (23). In addition, we showed that sildenafil induced delayed cardioprotective 
effect in the mouse heart through upregulation of iNOS and eNOS (31).  The hypothesis 
behind these studies was that vasodilatory action of sildenafil could potentially release 
endogenous mediators of preconditioning such as adenosine, bradykinin, or NO. One or 
more of these mediators may trigger signaling cascade leading to opening of the mitoKATP 
channel resulting in acute and delayed cardioprotective effects (23). There is substantial 
experimental evidence that one of the major intracellular signal transduction pathways 
controlling cardiac protection by ischemic preconditioning involves activation of PKC (24, 
36). The question posed in this study was whether PKC plays a pivotal role in sildenafil-
induced cardioprotection and to identify the specific isoform(s) may be involved in the 
protective role of sildenafil.  Our data show that translocation of PKC -θ and -δ started to 
increase after 30 min of sildenafil treatment, reached to significantly increased level after 
120 min of sildenafil treatment, which coincided with the ischemia protocol performed 60 
min after oral administration of sildenafil.  Although statistically non-significant, there was 
well-defined trend towards increase in the translocations of PKC -α, -θ and -δ with respect 
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to control at 30 and 60 min after sildenafil treatment.  Our data shows that administration 
of chelerythrine, the blocker of PKC prior to sildenafil abolished the infarct limiting effect 
of sildenafil following ischemia/reperfusion. The reduction in infarct size was not altered 
by vehicle (i.e., DMSO) confirming that the blockade of protection was indeed due to 
chelerythrine only.  Furthermore, chelerythrine did not have significant effect on infarct 
size in the sham ischemic/reperfused rabbit hearts suggesting that PKC antagonist 
interceded the signal transduction cascade during sildenafil treatment only.  These data 
strongly indicate that PKC activation plays an important role in the signaling mechanisms 
leading to sildenafil-dependent cardiac protection in the rabbit heart.     
 
Endogenous PKC exists in various isoforms with specific tissue distribution and 
sensitivity. Translocation of PKC from cytosolic to particulate compartments is commonly 
used as an index of PKC activation which is not only limited to sarcolemmal membrane 
but also to cytoskeletal, mitochondrial and nuclear fractions.  In the present study, we 
identified and quantified different isoforms of PKC from cytosol and membrane fractions.  
Our results show significant translocation of PKC-α after 60 minutes of treatment with 
sildenafil.  PKC-α is the major calcium dependent PKC isoform located in the soluble 
fraction in resting neonatal cardiac myocytes and an increase in calcium concentration 
selectively translocates PKC-α to the particulate fraction (30). The activation of PKC-α is 
essential for the regulation of the Raf-Ras-Erk cascade by IGF1 (insulin-like growth factor 
1) (25) or by hypertrophic signaling in adult rat cardiomyocytes (10). Our results also 
showed significant translocation of PKC θ and δ from 30 min to 120 min by sildenafil.  
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While the translocation of PKC-α, δ and ε have been studied in various models of ischemic 
and pharmacological preconditioning, the role of PKC-θ in cardioprotection remains 
unknown. PKC-θ is present in T lymphocytes as well as skeletal muscle, and its role in T 
cell signaling has been studied extensively (11). In the primary myotubes from neonatal 
mouse hind limb muscle, a rapid translocation of PKC-θ to the membrane in response to 
treatment with the cholinergic receptor agonists, carbachol has been demonstrated (12).  It 
was suggested that recruitment of PKC-θ to the membranes of myotubes following 
carbachol treatment plays a role in modulation of the function of membrane proteins, 
including receptors. Carbachol and PMA also caused an increase in PKC-α levels in the 
cytosol followed by its increase in membrane fractions (12). Inagaki et al. (6) showed that 
JTV519, a novel drug that has protective effect against Ca2+ overload-induced myocardial 
injury, provided anti-ischemic effect via specific activation of PKC-δ in rat hearts. 
Miyawaki and Ashraf (18) demonstrated that high calcium preconditioning evoked the 
translocation of PKC-α and PKC -δ to the cell membrane. In addition, PKC-  was 
translocated to the intercalated disk and suggesting that PKC-  may modulate myocardial 
function through cell-to-cell interactions.  Kawamura et al., 1998 (8) showed that ischemic 
preconditioning translocates PKC-α, -δ and -ε, but translocation of PKCα was transient in 
isolated rat heart. Under low Ca2+ perfusion, preconditioning suppressed translocation of 
PKC-α, and -ε, but not PKC-δ suggesting that the translocation of calcium-independent 
PKC-δ is essential for mediating ischemic preconditioning. The difference of the 
preconditioning procedures may also influence the importance of the PKC isoforms in 
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mediating the protective effect (8). Pathophysiological stimuli including heat shock and 
combination of heat shock and ischemic preconditioning also resulted in the translocation 
of PKC-α and -δ in young rats (5) further supporting the importance of these isoforms for 
the signaling cascade in cardioprotection. The downstream targets of PKC mediated 
cardioprotection involves multiple signaling pathways which include activation of MAP 
kinases e.g. ERK 1/2 and p38 kinases (19, 22, 26, 38, 41).  Recently, we demonstrated an 
essential role of PKC-δ in the delayed cardioprotection triggered by stimulation of 
adenosine A3 receptor subtype in the mouse (40). In these studies, the selective early 
translocation of PKC-δ in the membrane fraction initiated downstream signaling involving 
activation of transcription factor NFκβ, generation of NO and opening of the 
mitochondrial KATP channels (39), the possible mediators of delayed pharmacological 
preconditioning in the heart.  
 
In conclusion, for the first time we have demonstrated that sildenafil-induced 
cardioprotection is dependent on activation of PKC. Our results also show that selective 
translocation of three PKC isoforms (i.e., α, δ, θ) from cytosol to membrane fractions 
suggesting their potential role in sildenafil-induced cardioprotection.   Further 
investigations are needed to determine the cause and effect of each of the translocated PKC 
isozymes in sildenafil-induced cardioprotection and to understand the mechanism(s) by 
which translocated isozymes orchestrate downstream targets involved in attenuation of 
ischemic injury. These studies would help in expanding our knowledge on using this drug 
for protection of ischemic myocardium in humans. 
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FIGURE LEGENDS 
 
Figure 1.  Experimental protocols showing (A) Infarct study after oral administration of 
sildenafil citrate and/or intravenous administration of PKC inhibitor-chelerythrine and (B) 
PKC measurement following oral administration of sildenafil.  
 
Figure 2.  Bar diagram illustrates infarct size (% risk area) (A) and risk area (% left 
ventricle) (B) after oral administration of sildenafil citrate and/or intravenous 
administration of PKC inhibitor- chelerythrine following ischemia and reperfusion. Saline 
control, rabbits received 0.9 % saline. Sil, rabbit received 1.4 mg/kg sildenafil 60 min 
before ischemia-reperfusion. Sil + Che, chelerythrine was administered 5 min. prior to 
sildenafil treatment. Che, chelerythrine was given alone 65 min before 
ischemia/reperfusion. DMSO, the solvent for chelerythrine was administered alone 65 min 
prior to ischemia/reperfusion protocol. Results are means ±SE in 6 rabbits in each group. 
*P< 0.05 compared with saline control, sildenafil, sildenafil + chelerythrine , chelerythrine, 
and DMSO. 
 
Figure 3. Effect of sildenafil on subcellular localization of PKC-α (A), -θ (B), -δ (C), -β 
(D)  and -ε (E) in rabbit heart. Western blot showed subcellular distribution of PKC 
isoforms between cytosolic and membrane fractions after 30 min (S-30min), 60 min (S-
60min) and 120 min (S-120min) treatment with sildenafil. Densitometric analysis showed 
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the average of the ratio of each isoform with respect to β-actin level from 4 individual 
hearts per treatment group. *P< 0.05 compared with saline control and S-120 min. 
 
ABBREVIATIONS : Che, Chelerythrine; PKC, Protein kinase C; Sil,  
Sildenafil Citrate(Viagra). 
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          Table 1.  Hemodynamic Data 
  
 
Baseline Pre-
ischemia 
 
30-min 
Ischemia 
 
Reperfusion 
(60 min) 
 
Reperfusion 
(120 min) 
 
Reperf 
(180 min) 
Group I. (Saline Control, n=6) 
HR 
MAP 
RPP 
199 ± 8 
94 ± 3 
21072 ± 
950a,b,c 
213 ± 9 
84 ± 4d 
20896 ± 
842 
209 ± 9 
79 ± 4d 
19067 ± 
781a 
191 ± 10 
73 ± 3d 
16138 ± 
855a,d,e,f 
182 ± 10 
  72 ± 3d 
   15341±  
978d,e,f 
179 ± 10 
67 ± 2d,e 
13969 ± 
819a,d,e 
Group II. (Sildenafil, n=6) 
HR 
MAP 
RPP 
216 ± 5 
100 ± 2 
24859 ± 
239 
210 ± 20 
95 ± 3 
22848 ± 
2027 
216 ± 18 
96 ± 6 
23137 ± 
1617 
205 ± 14 
89 ± 0.4 
21647 ± 
2274 
187 ± 9 
82 ± 5d 
17738 ± 
860d 
187 ± 9 
81 ± 5d 
18555 ± 
1336 
Group III. (Sildenafil + Chelerythrine, n=6) 
HR 
MAP 
RPP 
181 ± 18 
102 ± 6 
14,573 ± 
1579a,e 
188 ± 9 
93 ± 4 
19,906 ± 
688 
172 ± 15 
78 ± 5d 
15,002 ± 
1181a,e 
194 ± 19 
69 ± 5d 
14,644 ± 
964a,e 
182 ± 17 
72 ± 5d 
14,647 ± 
1482e 
186 ± 18 
67 ± 11d 
14,261 ± 
1330a,e 
Group IV. (Chelerythrine, n=6) 
HR 
MAP 
RPP 
210 ± 8 
88 ± 4 
23,478 ± 
1021b,c 
200 ± 7 
84 ± 2 
20,259 ± 
1202 
188 ± 8 
80 ± 4 
18,398 ± 
1475a,d 
178 ± 7 
78 ± 6 
14,901 ± 
975a,d,e 
171 ± 7d 
70 ± 6 
16,987 ± 
1215d 
168 ± 11d 
71 ± 6 
13,579 ± 
986a,d,e,f 
Group V. (DMSO, n=6) 
HR 
MAP 
RPP 
177 ± 11 
90 ± 16 
17,585 ± 
846a,b 
200 ± 5 
77 ± 11   
18,345 ± 
1021 
209 ± 4 
66 ± 4a 
15,175 ± 
625a,e 
200 ± 16 
66 ± 11 
13,902 ± 
423a,d,e 
195 ± 4 
68 ± 12 
15,313 ± 
213e 
 
194 ± 2 
67 ± 10 
15,102 ± 
547a,e 
 
Values are means±SEM. HR-Heart Rate (beats/min); MAP-Mean Arterial Blood 
Pressure (mmHg); RPP- Rate Pressure Product (mmHg) aP<0.05 vs.Sildenafil; 
bP<0.05 vs.Sildenafil+ Chelerythrine; cP<0.05 vs DMSO; dP<0.05 vs. Baseline; 
eP<0.05 vs. Pre-ischemia; fP<0.05 vs. 30-min Ischemia. 
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CHAPTER 5 
Sildenafil Citrate (Viagra) Induces Cardioprotective Effects Following Ischemia-
Reperfusion Injury in Infant Rabbits 
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Division of Cardiology, Department of Medicine [F.S., R.O., E.C., R.C.K.], 
Virginia Commonwealth University Health System, Richmond, Virginia, U.S.A. 
 
Published in Pediatric Research in 2004. 
ABSTRACT 
 
Infants undergoing surgery for congenital heart disease are at risk for myocardial 
ischemia during cardiopulmonary bypass, circulatory arrest, or low flow states.  The 
purpose of this study was to demonstrate the effects of sildenafil, a selective 
phosphodiesterase-5 (PDE-5) inhibitor on myocardial functional improvement and infarct 
size reduction during ischemia/reperfusion injury in infant rabbits.  Infant rabbits (aged 8 
weeks) were treated with sildenafil citrate (0.7 mg/kg IV) or normal saline 30 minutes 
prior to sustained ischemia for 30 minutes and reperfusion for 3 hours.  Transesophageal 
echocardiography (TEE) was utilized to assess left ventricular cardiac output (LVCO) and 
aortic Velocity Time Integral (VTI).  Following ischemia/reperfusion, risk area was 
demarcated by Evan's blue dye and infarct size determined by computer morphometry of 
triphenyltetrazolium chloride stained sections.  The sildenafil-treated group had 
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preservation and elevation in LVCO (143% of baseline, p<0.05) and an elevated aortic 
VTI (145% of baseline, p<0.05) following 30 minutes of ischemia compared to the control 
group LVCO (72% of baseline, p<0.05) and aortic VTI (73% of baseline, p<0.05).  This is 
a statistically significant increase in LVCO and aortic VTI in the sildenafil group 
compared to controls (n=6/group, p<0.05).  The sildenafil treated group had significant 
reduction in infarct size (15.5 ± 1.2 versus 33 ± 2.3 in the saline group, % risk area, mean ± 
SEM, n=10-15/group, p<0.05).  For the first time, we have shown that sildenafil citrate 
promotes myocardial protection in infant rabbits as evidenced by post-ischemic 
preservation and elevation in LVCO and aortic VTI and reduction in infarct size. 
 
Abbreviations 
PDE-5, phosphodiesterase-5 
TEE, transesophageal echocardiography 
LVCO, left ventricular cardiac output 
VTI, velocity time integral 
TTC, 2,3,5-triphenyltetrazolium chloride 
LAD, left anterior descending 
LV, left ventricle 
LVOT, left ventricular outflow tract 
HR, heart rate 
MAP, mean arterial pressure 
SVR, systemic vascular resistance 
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Each year, more than 25,000 children undergo corrective surgery for congenital 
heart disease. Early surgical intervention is important to promote more normal 
development. Infants undergoing surgery for congenital heart disease are at risk for 
myocardial ischemia during cardiopulmonary bypass, circulatory arrest or low flow states 
(1).  Less is known about the tolerance of the infant myocardium to ischemia compared to 
the adult, and cardiac reserves are more limited in the infant (2).  Although there is 
evidence that the infant myocardium may be more resilient to metabolic or ischemic injury 
compared to adults, the infant heart responds quite differently to cardiovasular drugs, 
stress, and changes in hemodynamics (3,4).  Although hypothermia combined with 
pharmacologic cardioplegia protects the globally ischemic adult heart, this benefit may not 
extend to infants.  For example, poor post-ischemic recovery of function and increased 
mortality may result when this method of myocardial protection is used in children (5).  
Therefore, there is a need to develop novel pharmacological approaches to protect the 
infant hearts from ischemia/reperfusion injury.   
 Brief episodes of ischemia protect the myocardium from more prolonged periods of 
ischemia, a phenomenon called ischemic preconditioning (6).  A variety of other stimuli, 
such as hypoxia, thermal stress, pharmacologic agents, and endogenous triggers of 
preconditioning such as nitric oxide and adenosine have also been shown to induce 
cardioprotective effects in several animal species (7-10).  Also, recent studies from our 
laboratory have shown that sildenafil citrate (Viagra), a selective phosphodiesterase-5 
(PDE-5) inhibitor, induces powerful preconditioning-like protective effects in the ischemic 
heart (11).  However, it is not known whether sildenafil exerts similar protective effects 
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against ischemia/reperfusion injury in the infant rabbit hearts as well.  The purpose of this 
study was (a) to show if pretreatment of infant rabbits with clinically relevant dose of 
sildenafil improves post-ischemic myocardial function and (b) to demonstrate if this drug 
reduces myocardial infarct size following ischemia/reperfusion.  We used the model of 
coronary artery occlusion and reperfusion in infant rabbits, which is similar to our 
previously described adult rabbit model of myocardial infarction (11).  This model may be 
applicable in pediatrics, and especially in pediatric cardiovascular surgery where there may 
be periods of ischemia/reperfusion injury.  Also, for the first time, we used 2-dimensional 
(2D) and Doppler transesophageal echocardiography (TEE) for the estimation of left 
ventricular cardiac output (LVCO) and aortic velocity time integral (VTI) in this model.   
METHODS 
 
 
Animals.  Eight-week-old male New Zealand White rabbits with mean weight of 2.0 kg 
(range 1.3 kg-2.6 kg) were used for the study.  We chose Eight-week-old rabbits because 
they are similar in size to human neonates or young infants who undergo surgery for 
congenital heart disease early on in life.  We believe this model to be different from the 
adult rabbit model as well as helpful and similar to young human infants because of similar 
size, presence of thymic tissue (and thus not having had undergone significant stress yet), 
and being prepubertal.  We thus believe that the physiology and responses to stress and 
ischemia may be similar to that of human infants.    
Study Protocol.  Anesthesia and Infarction protocol are similar to those in Chapter 2. 
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TEE. Transesophageal echocardiography, using a 10 Fr AcuNav diagnostic ultrasound 
probe, was performed at baseline, following the 30 minute period of ischemia, and after 3 
hours of reperfusion in both the control and sildenafil groups.  Standardized 2D imaging in 
a long axis view of the left ventricle (LV) to show LV inflow across the mitral valve and 
left ventricular outflow tract (LVOT) was obtained (12) (Fig. 1).  Aortic flow Doppler 
across the aortic valve was performed in a long axis view of the LV and LVOT to obtain 
LVCO (Fig. 2).  The standard equation: Mean Velocity (cm/s) x flow area (cm2) x 60 
(s/min), where Mean Velocity (cm/s) = VTI (in cm/beat) ÷ RR interval in s/beat, was used 
to obtain LVCO expressed in mL/min (12,13).  Laminar Doppler flow across the aortic 
valve confirmed the absence of aortic stenosis.  Color Doppler assessment was made of 
both the aortic and mitral valves again in the long axis view at baseline, after the ischemic 
period, and following 3 hours of reperfusion for the presence or absence of mitral or aortic 
regurgitation.  Subjective functional assessment was also made following ischemia and 
reperfusion to demonstrate at least left ventricular apical diminished contractility to 
confirm infarction. 
Measurement of Infarct Size.  The same methodology was used here as previously 
dicussed in Chapter 2. 
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RESULTS 
 
Animals and Exclusion.  A total of 34 rabbits were used in the study; 20 in the sildenafil 
group and 14 in the control group.  2 rabbits in the control group died before completion of 
the 3 hour reperfusion period due to hypotension, arrhythmias and acidosis.  TEE was 
performed on 12 rabbits; 6 in the sildenafil group and 6 in the control group.  2 rabbits in 
the control group did not undergo TEE following 3 hours of reperfusion due to technical 
difficulties with the TEE machine.  A total of 25 rabbit hearts were examined for infarct 
size, 15 in the sildenafil group and 10 in the control group.  The 9 rabbit hearts that did not 
stain well were excluded from the study. 
Hemodynamics.  Changes in hemodynamics are summarized in Table 1.  The rabbits 
treated with sildenafil had a 34% decline in mean arterial pressure (MAP) and 8% increase 
in heart rate (HR) following drug administration as compared to the controls (p<0.05).  
However, MAP and HR were comparable in both groups prior to the ischemic period.  
Following 30 minute ischemia, MAP and HR were also comparable in both the groups 
although a significant decline in MAP as compared to the baseline values was observed.  
This drop in MAP persisted through 3 hours of reperfusion, which represented a 19% and 
18% decrease for the sildenafil and the control group respectively, compared to baseline 
values (p<0.05).  
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TEE.  Both the control and sildenafil-treated groups had comparable LVCO and aortic 
VTI at baseline.  The controls had a decline in LVCO and aortic VTI immediately 
following the 30 minute period of ischemia (28% and 27% lower than baseline values, 
respectively, p<0.05), whereas the LVCO and aortic VTI increased in the sildenafil group 
following ischemia (43% and 45% higher than baseline values, respectively, n = 6 per 
group, p<0.05).  Both groups, however, had significant decline in LVCO following 3 hours 
of reperfusion (54% of baseline in the sildenafil group, p<0.05, and 62% of baseline in the 
control group, p<0.05), and were not statistically significantly different from each other (n 
= 4-6 per group).  Both groups demonstrated a decrease in aortic VTI following 3 hours of 
reperfusion.  However, this decline was only statistically significant in the control group 
compared to baseline values.  Changes in LVCO and aortic VTI are shown in Figure 3.  
None of the rabbits had aortic stenosis or developed aortic regurgitation for the duration of 
the study.  Both the control and sildenafil groups demonstrated a comparable amount of 
mitral regurgitation (no more than mild) following ischemia/reperfusion, and none of the 
rabbits had baseline mitral regurgitation. 
Infarct Size.  Figure 4 shows risk area (% LV) and infarct size expressed as the % of risk 
area.  Pretreatment with sildenafil resulted in a decrease in the infarct size from 33 ± 2.3 in 
the control group to 15.5 ± 1.2 in the sildenafil treated rabbits, a 45% reduction compared 
to controls (p<0.05).  A similar trend in the changes in infarct size was observed when 
expressed as % of LV (not shown). Similarly, the differences between the risk areas were 
not statistically significant between the two groups.  These data suggest that changes in the 
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infarct size observed in the two groups was not related to the % of the area of LV occluded 
by our technique.   
 
DISCUSSION 
 
The use of sildenafil for treatment of erectile dysfunction by many patients with 
cardiovascular disease has resulted in a tremendous interest in the cardiovascular 
properties of the drug (14).  Recent studies in rats have shown that PDE-5 inhibition with 
sildenafil attenuated the rise in pulmonary artery pressure and vascular remodeling when 
given before chronic exposure to hypoxia and when administered as a treatment during 
ongoing hypoxia-induced pulmonary hypertension (15).  Clinical investigations in patients 
with pulmonary arterial hypertension have also shown that sildenafil therapy may be of 
benefit in patients receiving long-term infusion of epoprostenol (16,17).  Recently we 
reported that administration of sildenfil induced cardioprotection as indicated by 
significant reduction in infarct size when compared to controls (11,18).  In addition, we 
showed that sildenafil induced delayed cardioprotective effect in the mouse heart through 
upregulation of iNOS and eNOS (19).  The hypothesis behind these studies was that the 
vasodilatory action of sildenafil could potentially release endogenous mediators of 
preconditioning such as adenosine, bradykinin, or NO. One or more of these mediators 
may trigger a signaling cascade leading to activation of protein kinase C (20) and opening 
of the mitoKATP channel resulting in acute and delayed cardioprotective effects (11).  In the 
present study, we have shown that sildenafil citrate also induced cardioprotection against 
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ischemia/reperfusion injury in infant rabbits.  This is evident from preservation of post-
ischemic cardiac output and significant reduction in infarct size. 
Hemodynamics.  Sildenafil citrate had a direct effect on hemodynamics by causing 
transient hypotension, which may have resulted in increased heart rate either directly or 
indirectly.  Both groups developed the same degree of hypotension following ischemia 
even though the sildenafil-treated group had increased LVCO and aortic VTI.  This may 
reflect sildenafil’s effect on the lowering of systemic vascular resistance (SVR).  Since 
hypotension was again observed following the 3 hour reperfusion period in both groups, 
and LVCO was comparable even though infarct size was reduced in the sildenafil group, it 
is likely that LVCO and aortic VTI may be predominantly related to SVR.  We believe that 
sildenafil’s effect on SVR, which is not directly measured by pressure and heart rate, 
caused such a profound change and increase in cardiac output.  Thus, it is also possible that 
the additional benefits of sildenafil may be short-lived.  Our results suggest that multiple 
mechanisms may be involved in myocardial preservation with sildenafil infusion.  This 
may include a preconditioning-like effect as well as a direct effect on hemodynamics.  The 
drop in MAP in both groups following the 3 hour reperfusion period may reflect the fact 
that all rabbits were under general anesthesia for the duration of the experiment.  The 
rabbits did receive 50cc/hr of normal saline (~25cc/kg/hr), which is the approximate 
equivalent of several fluid boluses as given to human infants, although infused more 
slowly.  Since urine output was maintained throughout the experiment, we believe that 
renal function was preserved, and any excessive volume infused would have been 
accounted for by adequate urine output.  We would have expected hypertension and 
101 
bradycardia, or similar echocardiographic findings of increased output due to increased 
preload in both groups if volume had been an issue.  Thus it is unlikely that volume 
infusion alone led to hemodynamic deterioration in both groups after the reperfusion 
period. 
Functional assessment.  In the present study, we used 2D and Doppler echocardiography 
for the estimation of LVCO and aortic VTI.  This may be a better marker for preserved or 
increased cardiac output.  The use of TEE in the infant rabbit provided a long axis view of 
the LV and LVOT to make these calculations.  This view also showed the mitral valve and 
a selective plane of the left ventricular myocardium. LVCO was preserved in the sildenafil 
treated group mainly because of increased aortic VTI.  Aortic VTI, when multiplied by 
cross-sectional area, gives a volume measurement, or in this case left ventricular stroke 
volume (13,21). When this is multiplied by heart rate, it gives left ventricular cardiac 
output (13,21).  Heart rate was similar in both groups following ischemia and reperfusion, 
so can not be assumed to be the major determinant.  In addition, the cross-sectional area of 
the aortic valve annulus remained essentially unchanged as well.  LVCO was elevated in 
the sildenafil group compared to its baseline values and compared to the control group 
following the ischemic period.  Since cardiac output is a function of preload, afterload, and 
contractility, this demonstrates the beneficial effects of sildenafil in preserving myocardial 
function through its effect on hemodynamics and SVR (afterload). We believe that 
sildenafil’s effect on SVR, which is not directly measured by pressure and heart rate, 
caused such a profound change and increase in cardiac output.  We can not assume this is 
due to myocardial contractility alone (since this was not directly measured).   It is likely 
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that sildenfil’s role in opening of mitoKATP channels contributed to less myocardial 
necrosis, and subsequently enhanced contractility, although this does not explain the 
decline in function in both groups following the 3 hour reperfusion period.  Perhaps to a 
lesser extent, sildenafil inhibited the degradation of cAMP (by its minor role in inhibiting 
PDE-3), and subsequently led to accumulation of ATP and improvement in contractility.  
In addition, it is possible that sildenafil may cause coronary vasodilation and thus lead to 
enhanced local and selective myocardial perfusion following an ischemic period, and 
again, improvement in contractility.  The decline in cardiac output following 3 hours of 
reperfusion in both groups suggests that functional protection with sildenafil may be short-
lived, and again, predominantly related to SVR.  It may also be related to undefined 
actions of the drug itself that have yet to be determined. 
 
Infarct Size.  In the present study, we observed significant decrease in the infarct size in 
the sildenafil treated group as compared to control rabbits.  However the degree of infarct 
reduction was 53 % in the infant model as compared to 68 % in the adult rabbits (11) 
during acute pretreatment with sildenafil.  The drug provided 75 % reduction in infarct size 
24 hrs after treatment in the mouse model of global ischemia and reperfusion (19).  The 
reason for these variations is not clear although it may be related to the physiologic 
differences in the resistance of the infant myocardium to ischemia or stress versus the 
difference in response of the infant myocardium to cardiovascular drugs.  Although the 
infant myocardium may be more tolerant of ischemia only, its response to stress, 
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hemodynamic changes, and pharmacologic agents may be very different, thus rendering 
the myocardium more susceptible to injury. 
 
Study limitations.  When using Doppler echocardiography to calculate LVCO, there are 
several fundamental assumptions.  First, that flow is laminar and organized; second, that 
the velocity profile is uniform across the aortic valve outlet; third, that the point of outflow 
used to calculate vessel cross-sectional area is circular; and fourth, that the point of 
measurement of cross-sectional area remains relatively constant without significant 
changes with hemodynamics (13,21).  We made every attempt to record Doppler tracings 
with the Doppler beam parallel with flow in the vessel and just above the aortic valve 
annulus, as this is the point at which maximal flow velocity should theoretically occur 
(13).  We also measured the cross-sectional area at the aortic valve annulus, as this area 
should be the flow-limiting point and most constant in relation to changes in 
hemodynamics (13).  Since LVCO is preload dependent, the presence of mitral 
regurgitation or aortic regurgitation may potentially have an effect on cardiac output.  
Although we did not account for the volume of mitral regurgitation, we did assess for its 
presence or absence.  Since this amount was subjectively similar in both groups, we 
assumed that LVCO would not be substantially affected in either group.  Neither group 
developed aortic regurgitation.  Our study is also limited to a single 2D image of the long 
axis of the left ventricle.  This view is not able to assess all segments of the left ventricular 
myocardium to quantitate regional wall motion abnormalities.  Although we were able to 
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subjectively determine diminished apical myocardial contractility following infarct, we 
limited our study to the assessment of aortic VTI and LVCO.  
 
Clinical implications.  For the first time, we have shown that sildenafil treatment resulted 
in post-ischemic early improvement in cardiac output during ischemia/reperfusion in infant 
rabbits.  In addition, the drug caused significant reduction in infarct size following 
ischemia/reperfusion.  Further studies are needed to determine the effects of hypotension 
alone, as well as duration and timing of drug administration on sustained preservation of 
myocardial function during reperfusion or days later during recovery.  Since less is known 
about the optimum method of myocardial preservation in infants compared to adults, there 
is impetus for studying and developing different strategies for improved surgical outcome.  
In addition, since postoperative management of infants with congenital heart disease is 
complicated by various physiologic differences and responses to ischemia, stress, and 
changes in hemodynamics, it is important to devise new techniques for ideal ICU care.  It 
is possible that sildenafil citrate may be clinically important in protection of the heart in the 
setting of cardiac surgery employing cardiopulmonary bypass, circulatory arrest, or low 
flow states in infants with congenital heart disease.   
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FIGURE LEGENDS 
 
Figure 1. Still frame 2D transesophageal echocardiogram of LVOT.  LA=left atrium, 
MV=mitral valve, LV=left ventricle, AV=aortic valve, AO=aorta, RV=right 
ventricle. 
 
Figure 2. Still frame Doppler across aortic valve, velocity vs time.   
 
Figure 3. LVCO and aortic VTI following sildenafil infusion during 
ischemia/reperfusion.  n = 4-6 per group. *p<0.05, †p<0.05 compared to 
baseline values.  
 
Figure 4. Bar diagram illustrating infarct size (% risk area) in controls vs the 
sildenafil group compared to risk area (% left ventricle). n = 10-15 per 
group. *p<0.05. 
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Table 1. Hemodynamic Data During Ischemia/Reperfusion 
 
 Baseline 
After 
Saline/Drug Preischemia
End 
Ischemia
Reperfusion Time 
(Hour) 
Cntrl     1 2 3 
MAP 
85.4± 
3.7 
84.3± 
3.4 
80.5± 
3.8 
73.1± 
4.3§ 
75.1±
3.4 
75.3± 
3.4 
69.7± 
3.5§ 
HR 
213.1± 
6.6 
213.8± 
7.1 
212.1± 
6.9 
206.1± 
6.9 
188.5±
7.4 
175.3± 
7.2 
169.7±
8 
        
SIL        
MAP 
84.8± 
3.7 
55.9± 
2.5* 
74± 
3.7† 
70.2± 
4‡ 
71.5±
3.2 
69.2± 
2.8 
69.1± 
2.8‡ 
HR 
218.3± 
6.6 
236.1± 
4.6* 
211.8± 
3.8† 
202.2± 
5 
180.2±
6.9 
174.1± 
7.2 
167.8±
7.1 
 
               Values expressed as means ± SEM. MAP=mean arterial pressure in mmHg; HR= 
               heart ratein beats per minute. n = 12-20 per group.  *p<0.05 vs controls; †p>0.05 
               vs controls; ‡p>0.05 vs controls but <0.05 vs baseline; §p<0.05 vs baseline. 
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CHAPTER 6 
 
Sildenafil Induces Delayed Preconditioning against Myocardial Infarction via iNOS 
Upregulation by Phosphorylation of ERK in Mouse Heart 
 
 
 
 
Background:  We previously demonstrated that sildenafil induces delayed preconditioning 
following global ischemia/reperfusion in the mouse heart via iNOS dependent pathway 
(Chapter 3).  In the current study, we investigated the role of MAP kinases in sildenafil-
induced cardioprotective signaling.   
Methods and Results: Adult male ICR mice were pretreated (i.p.) with either sildenafil 
(0.71 mg/kg, equivalent to 50 mg dose for 70 kg patient) or volume-matched saline. 
Selective inhibitors of p38 MAPK (SB203580, 1 mg/kg, i.p.) or MEK1 and 2 (PD 98059, 1 
mg/kg, i.p.) were administered 30 min before sildenafil.  The hearts were isolated 24 hours 
later and subjected to 20 min global ischemia and 30 min of reperfusion in Langendorff 
mode. Infarct size was measured by computer morphometry of TTC stained sections. Post-
ischemic myocardial infarct size (Mean±SEM; % of risk area) was reduced in mice treated 
with sildenafil (6.0±1.2) versus saline group (27.6±3.3; P<0.05; n=6/each). SB203580 did 
not block this protective effect (8.2±1.6 vs. 6.0±1.2 with sildenafil alone, p>0.05). In 
contrast, PD98059 treatment abolished the infarct limiting effect of sildenafil (22.18±2.76, 
p<0.05).  Sildenafil caused increased phosphorylation of ERK1/2 but not p38 MAPK 
within 30 min after treatment.  Furthermore, western blot analysis showed an elevation in 
iNOS protein levels 24 hrs after treatment with sildenafil, which was abolished by 
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PD98059. No significant changes in ventricular contractile function and heart rate were 
observed in sildenafil-treated group.  
Conclusion: We conclude that the sildenafil-induced delayed protection against global 
ischemia/reperfusion is mediated by signaling pathway involving phosphorylation of ERK 
and the subsequent upregulation of iNOS. 
 
INTRODUCTION 
 
Sildenafil citrate (Viagra) is the first oral agent approved for treatment of erectile 
dysfunction in men. It is a selective inhibitor of phosphodiesterase-5 (PDE-5), an enzyme 
that catalyzes the breakdown of a potent smooth muscle relaxing agent cyclic guanosine 
monophosphate (cGMP).  Sildenafil has been shown to cause moderate decrease in systolic 
and diastolic pressure because of the inhibition of PDE-5 in smooth muscles in the 
vascular bed. We hypothesized that such mild vasodilatory effect of sildenafil in coronary 
vasculature could potentially release vasoactive agents such as adenosine or bradykinin, 
and demonstrated the role of sildenafil in increasing levels of iNOS protein which in turn 
upregulate NO that may trigger preconditioning-like protective effect in the heart. 
Moreover, we recently showed that sildenafil caused acute and delayed protection against 
ischemia/reperfusion injury in vivo in the heart which was dependent on the opening of 
mitoKATP channel [88].  These studies were performed in an in situ rabbit model where the 
hearts were subjected to coronary artery occlusion followed by reperfusion. We also 
illustrated that sildenafil induced a powerful delayed cardioprotevtive effect against global 
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ischemia/reperfusion injury via iNOS-dependent pathway in an isolated perfused mouse 
heart model [90]. However, the signaling pathway(s) that lead to such cardioprotective 
effect are currently under investigation.   
 
Recent studies suggest an important role of the MAP kinase family particularly p38 in the 
early phase of ischemic preconditioning (IPC) [20], although the results have been 
controversial [92].   Direct activation of p38 by anisomycin mimicked IPC and delayed 
cardioprotection in the isolated perfused hearts [93,46]. The activation of p38 has also been 
suggested to be the trigger of delayed preconditioning induced by adenosine.  In the MAP 
kinase family, the p44/p42-MAPK (Erk1/2, where Erk is extracellular-signal-regulated 
kinase) cascade appears to mediate cell growth and survival signals in many cell types.  
ERK activation has been shown to protect cardiomyocytes from oxidant stress [94].  
Sustained activation of p44/p42-MAPK during simulated ‘reperfusion’ following sublethal 
simulated ‘ischemia’ mediates preconditioning in cardiomyocytes independently of 
transient activation of p38-MAPK.   However there are no studies available implicating the 
role of MAP kinases in sildenafil-induced cardioprotection.  The goal of the present 
investigation was to 1) to show if p38 MAPK and ERK 1 and 2 phosphorylation plays role 
in the sildenafil-induced cardioprotection, and 2) to investigate the role of MAPK 
phosphorylation in the sildenafil-mediated increase in iNOS and eNOS protein levels.  
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MATERIALS AND METHODS 
 
Langendorff Isolated Perfused Heart Preparation   
The same experimantal protocol was used as in Chapter3. 
 
Study Protocol 
Mice were randomly assigned into one of the following groups:  
 
Group I: (saline control, n=6): Mice received 0.9 % saline, i.p.;  
Group II:  (Sildenafil, n=6):  Viagra tablets were crushed and dissolved in saline.  This 
preparation was given as 0.71 mg/kg i.p. bolus, approximating, on a mg/kg basis, the 
clinical dose of 50 mg administered to a 70 kg patient; 
Group III: SB203580 + Sildenafil (n=6):  SB203580 (1.0 mg/kg) was injected 30 min prior 
to sildenafil treatment as in Group II;  
Group IV: SB203580 + Saline (n=6): treatment with SB203580 alone;  
Group V: PD 98059 (1.0 mg/kg) was injected 30 min prior to sildenafil;  
Group VI: PD 98059 + Saline (n=6): pretreatment with PD 98059 alone; 
 
Twenty-four hours later, the hearts were isolated and following a 30 min stabilization 
period, the hearts were subjected to 20 min no-flow normothermic global ischemia and 30 
min reperfusion.   
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Phosphorylation of p38, ERK 1 and 2:  Four animals were pretreated with 0.15 ml saline 
or 0.71mg/kg sildenafil (i.p., n=2 per group). Te hearts were removed, ventricular samples 
collected 30 min after treatment and immediately frozen in liquid nitrogen. The samples 
were ground into fine powder in liquid nitrogen after cell lysis in 1 ml of RIPA buffer 
(Upstate) containing: 5omM Tris-HCL, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 
1% NP-40, 1mM EDTA and protease inhibitors (1nM phenylmethylsulfonyl fluoride, 1 
µg/ml leupeptin, 1 µg/ml pepstatin and µg/ml aprotinin) and a phosphatase inhibitor (1 
mM sodium orthovanadate). The mixture was homogenized and centrifuged at 6,000 g for 
10 min. The supernatant was then collected and protein concentration was measured.   
For immunoprecipitation, 300 µg of the sample protein were incubated with 5 µg of anti-
p38 (C-20, Santa Cruz) or anti-ERK rabbit polyclonal antibody (C-14, Santa Cruz) in 
500 µl of RIPA buffer for 3 h at 4°C. 35 µl of protein A/G agarose beads (Santa Cruz) 
were then added to the sample and mixed for another 60 min. The agarose beads containing 
the immunocomplexes were pelleted by centrifugation for 5 min (1000 g) at 4°C, and the 
supernatant was carefully aspirated and discarded. The beads were washed 3 times with 
RIPA buffer and 1 time with PBS by repeating the centrifugation step described above. 
The beads were then resuspended in 50 µl of electrophoresis sample buffer. To dissociate 
the immunocomplexes from the beads, the sample was boiled for 5 min and centrifuged 
again, and the supernatant was collected. Subsequently 20 µl of immunoprecipitated 
supernatant were separated by SDS-PAGE (10% polyacrylamide) and transferred to a 
polyvinylidene difluoride membrane (Bio-Rad) via tank transfer for 2 h at 190 mA. After 
the membrane was blocked with milk solution [5% nonfat dry milk in Tris-buffered saline 
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(TBS) with 0.05% Tween-20 (TBST)] for 1 h, it was probed with a mouse monoclonal 
antibody for either phosphorylated p38 MAPK (p-p38, D-8; Santa Cruz) or phosphorylated 
ERK (p-ERK, E-4, Santa Cruz); or total p38 (A-12, Santa Cruz) or ERK-2 (D-2, Santa 
Cruz) [both diluted 1:500 in milk with TBST] for 2 h. After the membrane was washed 
with TBST, it was incubated with an anti-mouse horseradish peroxidase-linked antibody 
(diluted 1:2,000 in milk solution with TBST; Amersham) for 1 h. The membrane was 
washed with TBST four times (for a total of 30 min) and then incubated using a 
chemiluminescence kit (Amersham) before being exposed to X-ray film. The bands were 
quantified via densitometric scanning. 
 
Western Blot Analysis:   In brief, triplicate heart samples were collected 24 hours after 
saline , sildenafil, PD98059 followed by sildenafil 30 min later, or PD98059  injection and 
homogenized in ice-cold RIPA buffer (Upstate Biotechnology).  The homogenate was 
centrifuged at 10,000 g for 10 min under 4°C, and supernatant was recovered as the total 
cellular protein.  60 µg total protein from each sample was separated by SDS/PAGE on 
10% acrylamide gels and transferred to a PVDF membrane, and then blocked with 5% 
non-fat dry milk in TBS.  The membrane was subsequently incubated with a rabbit 
polyclonal antibody (Santa Cruz; dilution 1:500) reacting specifically to iNOS, eNOS, or 
actin (for normalizing loading of protein).  The secondary antibody was a horseradish 
peroxidase-conjugated anti-rabbit IgG (Amersham, 1:1,000 dilution).  The membranes 
were developed using enhanced chemiluminescence and exposed to x-ray film. 
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For quantifying protein expression, the optical density for each Western blot band was 
scanned and analyzed with a densitometric system (Bioquant 98). 
 
RESULTS 
 
Cardiac Hemodynamics and Contractile Function:  
There was no significant difference in the basal functional parameters (i.e. developed 
force, rate-force product, and resting tension) between the groups after 20 min 
stabilization.During post-ischemia also; there were no significant differences in the rate 
force product (Figure 1). Post-ischemic coronary flow was not significantly different 
among the groups except that it was slightly improved in the sildenafil-treated mice. 
 
Myocardial Infarction: 
Post-ischemic myocardial infarct size (Mean±SEM; % of risk area) was reduced in mice 
treated with sildenafil (6.0±1.2) versus saline group (27.6±3.3; P<0.05; n=6/each). 
SB203580 did not block this protective effect (8.2±1.6 vs. 6.0±1.2 with sildenafil alone, 
p>0.05). In contrast, PD98059 treatment abolished the infarct limiting effect of sildenafil 
(22.18±2.76, p<0.05).  There was no significant difference in the infarct size between the 
controls and the animals treated with DMSO, PD98059 and SB203580.   
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Phosphorylation of p38 and ERK: 
Ventricular tissue was harvested after 30 minutes of treatment with sildenafil.   
Phosphorylation of p38-MAPK and p44/p42-MAPK (Erk1/2) was determined by Western 
blotting using phospho-specific antisera. As shown in Figure 2, phosphorylation of both 
p42- and p44-MAPK isoforms was observed.  Total p42-MAPK (Erk2) is shown in the 
upper panel as a loading control.  Phosphorylated p38 or total p38 was not different 
between control and sildenafil treated mice. 
 
Effect of ERK activation on iNOS/eNOS protein expression: 
Heart samples were collected 24 hours after saline, sildenafil, PD98059 and followed by 
sildenafil, or PD98059 injection.  Protein levels of iNOS/eNOS were determined by 
Western blotting. As shown in Figure 3, iNOS protein expression is increased with 
sildenafil as compared to the saline control group, and this increase is completely blocked 
by PD98059 pretreatment.  
 
 
 
DISCUSSION 
 
The expression of the iNOS gene is an important part of the body’s response to stressors by 
modulating and regulating vascular smooth muscle tone and thus affecting function of 
several organ systems, including the cardiovascular system. The NO generated by iNOS 
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from its substrate L-arginine has beneficial effects (eg, antimicrobial, antiatherogenic, 
antiapoptotic), whereas the overproduction of induced NO has detrimental consequences 
(eg, direct cellular injury and proinflammatory response). Sildenafil pretreatment was 
shown to induce upregulation of iNOS, but the exact mechanism of this effect is not yet 
fully understood.   Studies have suggested that the iNOS gene is regulated at multiple 
levels: transcriptional, posttranscriptional, and posttranslational. However, the role of the 
mitogen-activated protein kinase (MAPK) cascades in the control of iNOS expression has 
not been completely defined. In this study, we investigated whether the MAPK signaling 
pathway was involved in the regulation of iNOS expression and whether sildenafil 
influenced MAPK activity.  In the present study, a single bolus injection of sildenafil of 
0.71 mg/kg caused significant reduction in the infarct size 24 hrs later, when compared to 
the saline-treated controls.  The selective inhibition of ERK by PD98059 completely 
abolished the protective effect of sildenafil whereas p38 MAPK inhibitor SB203580 failed 
to block the protection.  These results are further supported by increased phosphorylation 
of p44/42 sildenafil treated hearts while absence of phosphorylated p38 in the same 
samples.  No significant changes in the pre- or post-ischemic ventricular function were 
observed between the control and treated groups.  Taken together, our results show that 
phosphorylation of ERK 1 and 2 mediates sildenafil induced delayed cardioprotection 
against global ischemia/reperfusion injury. 
 
The role of p38 signaling in early preconditioning has been extensively investigated, 
although conflicting results have been obtained.  However, relatively little is known about 
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the role of MAP kinases, in particular their cause and effect during delayed 
preconditioning.  Ping et al [32] demonstrated that ischemic PC was associated with 
activation of p44 and p42 MAPKs in rabbit hearts although the role of these kinases in 
delayed protection in this model was not studied.  Recently we showed that heat stress-
induced delayed protection was mediated by MAP kinases.  Dana et al [78] showed 
transient activation of adenosine A1 receptor with 2-chloro-N6-cyclopentyladenosine 
(CCPA) induced delayed preconditioning which was also accompanied by rise in the p38 
activity.  The delayed protection was abolished by p38 inhibitor, SB203580 in the mouse 
heart suggesting an essential role of p38 in protection. Recently, we showed that selective 
activation of p38 with anisomycin triggered delayed cardioprotection in the mouse heart. 
In this respect, it appears that sildenafil is the first drug which mediated delayed 
cardioprotection through phosphorylation of ERK 1/2.   
 
In summary, we demonstrated that a significant ERK phosphorylation can be detected with 
0.71 mg/kg i.p. administration of sildenafil, which is in a dose range that is clinically 
relevant. The results provide a possible mechanism to explain the potential infarct-limiting 
effect of sildenafil and suggest that ERK activation by this PDE-5 inhibitor may be 
involved in the subsequent induction of iNOS expression.  
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Figure Legends 
 
 
Figure 1. Experimental protocol for Langfendorff isolated moude heart experiments. 
 
Figure 2. Effect of sildenafil, SB203580, and PD98059 on ventricular functional recovery 
following global ischemia-reperfusion. 
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Figure  3.   Effect of sildenafil on myocardial infarct size: role of p38 MAPK and p44/42 
MAPK.  Isolated perfused hearts were subjected to 20 min global ischemia and 30 min 
reperfusion in Langendorff mode. Values are means ± SE (n = 6 heart samples per group).  
Group III and V received SB-203580 (1 mg/kg, ip) or PD 98059 (1 mg/kg, ip) 30 min 
before sildenafil treatment.  Group IV and VI served as controls for SB203580 and 
PD98059, respectively. *P < 0.05 vs. saline control, SB203580+saline, 
PD98059+sildenafil and PD98059+saline. 
 
Figure 4.  Western blots showing MAPK phosphorylation after treatment with sildenafil. 
Tissue homogenates were immunoprecipitated with a mouse monoclonal 
antiphosphotyrosine antibody combined with protein A/G plus agarose. 
Immunoprecipitates were subsequently analyzed by Western blots using a mouse 
monoclonal antibody for a 1:100 dilution of either total and phosphorylated p38 MAPK or 
total and phosphorylated anti-ERK 1 and 2 rabbit polyclonal antibody. 
 
 
Figure 5.  Western blots showing cardiac expression of iNOS and eNOS proteins 24 hrs 
after sildenafil treatment with or without PD98059.  Actin levels for each sample shows 
equal protein loading. 
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Figure 4 
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Figure 5 
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CHAPTER 7 
 
 
 
Delayed Cardioprotection with Sildenafil in Mice: Role of Adenosine A1 Receptor 
and Its Genetic Deletion 
 
Background: Since adenosine has been implicated to be a major trigger of  schemic and 
pharmacological PC, we tested the hypothesis that A1 adenosine receptor (A1AR) 
activation plays a role in sildenafil-induced cardioprotective signaling.   
Methods and Results: Adult male C57BL-wild type (WT) mice or their corresponding 
A1AR-knock out (KO) mice were pretreated (i.p.) with either sildenafil (0.71 mg/kg, 
equivalent to 50 mg dose for 70 kg patient) or volume-matched saline. The selective A1AR 
antagonist DPCPX (0.1 mg/kg, i.p.) was administered 30 min before sildenafil.  The hearts 
were isolated 24 hours later and subjected to 30 min global ischemia and 1 hr of 
reperfusion in Langendorff mode. Infarct size was measured by computer morphometry of 
TTC stained sections. Post-ischemic myocardial infarct size (Mean±SEM; % of risk area) 
was reduced in C57BL-WT mice treated with sildenafil (5.6±0.9) versus saline group 
(27.3±2.1; P<0.05; n=6/each). Sildenafil failed to precondition the A1AR-KO hearts 
(31.6±1.9 vs. 32.3±1.5 with saline, p>0.05). Additionally, DPCPX treatment abolished the 
infarct limiting effect of sildenafil (27.3±3.2, p<0.05).  DPCPX alone had no effect on 
infarct size as compared with the control group.  No significant changes in left ventricular 
pressure and heart rate were observed in sildenafil-treated group.  
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Conclusion: The sildenafil-induced delayed protection against global ischemia/reperfusion 
is mediated by signaling pathway involving the interaction of endogenous adenosine with 
its A1 receptor. 
 
INTRODUCTION 
 
Adenosine receptor activation following PC protects the heart against reversible 
and irreversible ischemic injury in multiple species and preparations (97,98). As described 
in the previous section, our initial studies demonstrated the cardioprotective effect of 
sildenafil in several animal species. The hypothesis behind these studies was that the 
release of endogenous mediators such as adenosine, bradykinin or NO following sildenafil 
treatment. This in turn could potentially trigger signaling pathways leading to 
cardioprotection.  
Since we previously demonstrated the importance of ERK activation and iNOS 
upregulation in cardioprotection with sildenafil, and since other studies have already 
demonstrated the link between A1AR and iNOS, we examined the possibility of A1AR 
contribution to the PC-like effect afforded by sildenafil. We hypothesized that sildenafil, 
through its hypotensive effects, would potentially lead to the release of adenosine from 
cells into the interstitial fluid, thus making adenosine available to interact with its 
receptors. This mimics, to a certain extent, the release of small amounts of adenosine 
observed during brief episodes of ischemia that leads to PC against subsequent prolonged 
ischemia. In the present study, we took advantage of adenosine A1 receptor knock-out 
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mice and selective A1 receptor antagonist DPCPX to elucidate the role of A1AR in 
inducing delayed cardioprotection in mice. The goals of the study are as follows: 
1) to determine whether sildenafil could confer cardioprotective effects in the C57BL-WT 
mice similar to ICR outbred mice shown previously; 2) to show if sildenafil confers 
delayed cardioprotection in A1AR-KO mice and following inhibition of the receptor in 
WT mice with the selective A1AR antagonist DPCPX; and 3) to demonstrate that 
sildenafil induces protection against simulated ischemia/reoxygenation in mouse 
cardiomyocytes derived from WT and A1AR-KO mice. 
 
 
Materials and Methods 
Animals  
  Adult male C57BL mice were supplied by The Jackson Laboratory (Bar Harbor, 
ME. The body weight for these animals ranged between 27.1 and 32.7 g.  A1AR-KO mice 
were provided by The National Institute of Diabetes and Digestive and Kidney Diseases, 
National Institutes of Health, Bethesda, MD 20592; PI Dr. Jurgen Schnermann.  
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Langendorff Isolated Perfused Heart Preparation   
 
The methodology of the Langendorff isolated perfused heart has been described in 
previous chapters. The only difference in the current study in the use of left ventricular 
developed pressure as opposed to ventricular contractile function. To obtain the developed 
pressure, a left atrial incision was made to expose the mitral annulas through which a 
water-filled latex balloon was passed into the left ventricle (LV). The balloon was attached 
via polyethylene tubing to a Gould pressure transducer that was connected to a PowerLab 
Acquisition System (ADInstruments 8SP, Australia). The balloon was inflated to adjust the 
LV enddiastolic pressure (LVEDP) to _10 mmHg. Myocardial ischemic damage was 
measured using multiple, independent end points of tissue injury. These included infarct 
size, LV developed pressure (LVDP), LVEDP, rate-pressure product (RPP), heart rate, and 
coronary flow by timed collection of the perfusate. LVDP was calculated by subtracting 
LVEDP from the peak systolic pressure. RPP, an index of cardiac work, was calculated by 
multiplying LVDP with heart rate.  The hearts were not paced.   
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Study Protocol 
 
Mice were randomly assigned into one of the following groups:  
 
Group I: (saline control, n=6): WT mice received 0.9 % saline, i.p.;  
Group II: (saline control, n=6): A1AR-KO mice received 0.9% saline, i.p.; 
Group III:  (Sildenafil, n=6):  Wt mice; pure sildenafil powder provided by Pfizer, Inc.was 
dissolved in saline.  This preparation was given as 0.71 mg/kg i.p. bolus, approximating, 
on a mg/kg basis, the clinical dose of 50 mg administered to a 70 kg patient; 
Group IV: (Sildenafil, n=6):  A1AR-KO mice received 0.71 mg/kg sildenafil as in Group 
III;  
Group V: (DPCPX+sildenafil n=6): WT mice; treatment with DPCPX (0.1mg/kg) 30 min 
prior to sildenafil treatment as in Group III  
Group VI: (DPCPX+saline n=6): WT mice; treatment with DPCPX (0.1mg/kg) 30 min 
prior to saline treatment as in Group I. 
 
Twenty-four hours later, the hearts were isolated and following a 30 min stabilization 
period, the hearts were subjected to 30 min no-flow normothermic global ischemia and 1 
hr reperfusion.   
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Another subset of mice was used for adult cardiomyocyte isolation as described later in 
this section. The isolated cardiomyocytes were subjected to hypoxia/reoxygenation to 
simulate ischemia/reperfusion in the intact heart. Different study groups were randomly 
assigned in order to assess the role of sildenafil in cardioprotection in vitro as well as 
evaluating the role of the A1AR in the sildenafil induced protection. 
 
Isolation of adult mouse ventricular cardiomyocytes:  Adult male C57BL-WT (The 
Jackson Laboratory, Bar Harbor, ME) or A1AR-KO mice (National Institute of Diabetes 
and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20592; PI 
Dr. Jurgen Schnermann) were used in this study. The animal experimental protocols were 
approved by the Institutional Animal Care and Use committee of Virginia Commonwealth 
University. The ventricular cardiomyocytes were isolated using an enzymatic technique 
modified from the previously reported method (95,96). In brief, the animal was 
anesthetized with pentobarbital sodium (100 mg/kg, i.p.) and heart was quickly removed. 
Within 3 min, the aortic opening was cannulated onto a Langendorff perfusion system and 
heart was retrogradely perfused (37oC) at a constant pressure of 55 mmHg for ~5 min with 
a Ca2+-free bicarbonate-based buffer containing (in mM): 120 NaCl, 5.4 KCl, 1.2 MgSO4, 
1.2 NaH2PO4, 5.6 glucose, 20 NaHCO3, 10 2,3-butanedione monoxime, and 5 taurine, 
which was continuously bubbled with 95%O2 + 5%CO2. The enzymatic digestion was 
commenced by adding collagenase type II (Worthington, 0.5 mg/mL each) and protease 
type XIV (0.02 mg/mL) to the perfusion buffer and continued for ~15 min. 50 µM Ca2+ 
was then added in to the enzyme solution for perfusing the heart for another 10-15 min. 
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The digested ventricular tissue was cut into chunks and gently aspirated with a transfer 
pipette for facilitating the cell dissociation. The cell pellet was resuspended for a 3-step 
Ca2+ restoration procedure (i.e. 125, 250, 500 µM Ca2+). The freshly isolated 
cardiomyocytes were then suspended in minimal essential medium (Sigma catalogue# 6 
M1018, pH 7.35-7.45) containing 1.2 mM Ca2+, 12 mM NaHCO3, 2.5% fetal bovine serum 
and 1% penicillin-streptomycin. The cells were then plated onto the 35 mm cell culture 
dishes, which were pre-coated with 20 µg/mL mouse laminin in PBS + 1% penicillin-
streptomycin for 1 hour. The cardiomyocytes were cultured in the presence of 5% CO2 for 
1 hour in a humidified incubator at 37oC, which allowed cardiomyocytes to attach to the 
dish surface prior to the experimental protocol. 
 
Experimental Protocol 
 
The cultured cardiomyocytes were incubated under 37oC and 5% CO2, for 1 hour with or 
without 1 µM sildenafil citrate powder, dissolved in distilled water. The drug solution was 
filtered (0.45 µm pore size) before adding into cell medium. Cardiomyocytes were 
subjected to SI for 40 minutes by replacing the cell medium with an “ischemia buffer” 
which contained (in mM): 118 NaCl, 24 NaHCO3, 1.0 NaH2PO4, 2.5 CaCl2-2H2O, 1.2 
MgCl2, 20 sodium lactate, 16 KCl, 10 2-deoxyglucose (pH adjusted to 6.2). In addition, the 
cells were incubated under hypoxic conditions at 37oC during the entire SI period by 
adjusting the tri-gas incubator to 1-2% O2 and 5% CO2. RO was accomplished by replacing 
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the ischemic buffer with normal medium under normoxic conditions. Assessment of cell 
necrosis and apoptosis was performed at 18 hours of RO. 
 
Evaluation of Cell Viability:    Cell viability was assessed by trypan blue exclusion assay. 
At the end of protocol, 20 µL of 0.4% trypan blue (Sigma-Aldrich) was added into the 
culture dish. After ~5 min of equilibration, the cells were counted under microscope.  
 
Statistics: All measurements are expressed as means ± SE. The data were analyzed by 
either unpaired t-test or one-way ANOVA. If a significant value of F was obtained in 
ANOVA, the Student-Newman-Keuls post hoc test was further used for pairwise 
comparisons. Paired t-test was used to compare any pair of pre- and post-treatment values 
for the same parameter. P < 0.05 was considered significant.  
 
 
RESULTS 
 
Cardiac Hemodynamics and Contractile Function:  
There was no significant difference in the basal functional parameters (i.e. developed 
LV pressure, rate-pressure product, and EDP) between the groups after 20 min 
stabilization. During post-ischemia also, there was a significant increase in the rate 
pressure product (Figure 1) only in the sildenafil-treated group. Post-ischemic coronary 
flow was not significantly different among the groups. 
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Myocardial Infarction: 
 
Post-ischemic myocardial infarct size (Mean±SEM; % of risk area) was reduced in wild 
type mice treated with sildenafil (5.6±0.9) versus saline group (27.3±2.1; P<0.05; 
n=6/each) (Figure 2). On the other hand, sildenafil did not offer any protection in the 
A1AR-KO mice (31.6±1.9 vs. 32.3±1.5 with saline, p>0.05). Moreover, the selective 
A1AR antagonist DPCPX completely blocked the infarct-limiting effect of sildenafil in the 
wild type mice (27.3±3.2, p<0.05).  There was no significant difference in the infarct size 
between the controls and the animals treated with DPCPX or DMSO, the solvent for 
DPCPX.   
 
 
Effect of Sildenafil on Cardiomyocyte Necrosis 
 
 
Our method for cell preparations yielded a relatively high percentage of the 
cardiomyocytes with rod shape morphology, which was similar to previously reported 
studies (95,96). 
After 40 min of SI and 18 hours of RO, the trypan blue positive cardiomyocytes reached 
53±2.8%. However, prior treatment with sildenafil reduced the trypan blue positive cells as 
compared with untreated SI-RO group (24.5±2.6, p<0.05, n=3; Fig 3). The A1AR selective 
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antagonist, DPCPX, abolished the protective effect of sildenafil as shown by an increase in 
the trypan blue positive cells which was not different from control (50.8±3.0). 
Interestingly, in the cardiomyocytes obtained from A1AR-KO mice, sildenafil failed to 
protect the myocytes against necrosis caused by H/R as compared with control (46.7±2.3 
vs 51.9±4.4). DPCPX or its solvent DMSO alone had no effect on trypan blue positive cell 
count. 
 
Discussion 
 
 Since sildenafil causes a hypotensive response, it is possible that adenosine would 
be released and consequently interacts with its receptors potentially leading to a 
preconditioning-like effect. Accordingly, the previously reported cardioprotective effect of 
sildenafil could be mediated by A1AR.   In the present study, we used a reltively selective 
approach by employing mice showing genetic deletion of the A1AR and we investigated 
the role of the A1AR in the sildenafil-induced preconditioning-like effect.   As our recent 
results show, sildenafil did in fact confer powerful cardioprotection against I/R injury in an 
isolated mouse heart model of I/R. This protection was abolished by both the selective 
A1AR antagonist DPCPX and genetic deletion of A1AR.  Furthermore, in the isolated 
adult cardiomyocyte derived from wild-type mice, the trypan blue positive necrotic cells 
were significantly lower in the sildenafil-treated group as compared with the saline treated 
control myocytes. Also, sildenafil-induced protection was abolished by A1AR antagonist, 
DPCPX and cells obtained from A1AR-KO mouse cardiomyocytes treated with sildenafil. 
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Adenosine receptor subtypes, including the A1 and A2a receptors, have been reported to 
couple to the ERK pathway in both cardiac and noncardiac tissues. It has also been 
reported that the beneficial effects of adenosine A2a receptor activation during reperfusion 
appear to be due to ERK activation (107). However, thusfar, there have been no studies 
examining whether adenosine receptor PC is mediated via ERK. Although the results of a 
significant number of studies suggest that ERK activation during ischemia-reperfusion is 
beneficial, there are additional reports suggesting otherwise. The discrepancies in the exact 
role of ERK activation in myocardial ischemia-reperfusion may be due to the specific 
stimulus and the duration of ERK activation. Despite the key role for mitochondria in 
mediating the beneficial effects of PC, as well as contributing to reperfusion oxidative 
stress, and a report that ERK isoforms are present in murine heart mitochondrial fractions 
(108), there have been no reports examining mitochondrial ERK activation during PC or 
myocardial ischemia/reperfusion. 
 
 Our present results raise a very interesting topic as to how sildenafil could afford 
cardiomyocyte protection against H/R in the absence of the hypotensive effect. If the mild 
drop in blood pressure due to cGMP accumulation is what caused adenosine release in vivo 
as we initially hypothesized, then there probably is some other mechanism through which 
sildenafil is effective against necrosis from H/R in vitro. It is possible that cGMP formed 
after treatment with sildenafil somehow affects the A1AR sensitivity and thus allows more 
adenosine to re-enter the cell after its release during hypoxia and thus generating a 
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preconditioning-like effect. More research is needed to address this interesting finding and 
further investigate the exact cause-and-effect relationship between sildenafil and the 
A1AR. 
In conclusion, we have demonstrated in the current study that genetic deletion of A1AR 
abolishes the cardioprotective effects of ischemic preconditioning as well as 
pharmacological preconditioning with the PDE-5 inhibitor sildenafil. Our findings do in 
fact corroborate a key role of A1AR activation in the subcellular mechanisms of 
myocardial protection against I/R injury. 
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Figure Legends 
 
Figure  1.     Experimental protocol showing the various groups. 
 
Figure 2.   Effect of sildenafil, DPCPX, and genetic deletion of A1AR on ventricular 
functional recovery following global ischemia-reperfusion. 
 
Figure 3.   TOP: Representative heart sections showing infarction (white) with 10% TTC 
staining. More viable tissue (red) is prominent in the sildenafil-treated WT mice as 
compared to the A1AR-KO mice and DPCPX-treated mice. 
BOTTOM: Effect of sildenafil on myocardial infarct size: role of A1AR.  Isolated perfused 
hearts were subjected to 30 min global ischemia and 1hr reperfusion in Langendorff mode. 
Values are means ± SE (n = 6 heart samples per group).  Group III (WT) and IV (A1AR-
KO) received sildenafil (0.71 mg/kg, ip). Group V received DPCPX (0.1 mg/kg) 30 min 
before sildenafil treatment.  Group (I, II) and (VI) served as controls for sildenafil and 
DPCPX, respectively. *P < 0.05 vs. sildenafil+WT. 
 
Figure 4.   Necrotic index using trypan blue in adult ventricular cardiomyocytes obtained 
from wild type and A1AR-knock out mice.  
 
Figure 5.    Digital photo showing an adult mouse heart being perfused in Langendorff 
mode.  
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Chapter 8 
General Discussion 
 
Phosphodiesterase type-5 (PDE-5) inhibitors 
 
PDE-5 inhibitors are a new class of vasoactive drugs that have been developed for 
treatment of ED in men. Their main mechanism of action is through the active inhibition of 
PDE-5 enzyme thus allowing accumulation of cGMP resulting in smooth muscle 
relaxation in the penis. So far, there are 11 known families of PDEs  shown to exist in 
mammalian tissues.  Even though PDEs are expressed in all tissues, the distribution of the 
various isoforms may differ among various tissues and cell types.  These enzymes play a 
key role in modulating diverse physiological processes.  
Sildenafil citrate (ViagraTM) is the first oral agent approved for treatment of ED in men.  Its 
chemical structure is similar to that of cGMP and therefore inhibits PDE-5 by binding to 
the cGMP-catalytic sites (Corbin and Francis, 2002), resulting in the accumulation of 
cGMP in the erectile tissue.   
 
Cardioprotection with sildenafil against I/R injury  
 
For a little over three years now, sildenafil has been investigated as a candidate for 
pharmacological PC against I/R injury in animal models. Due to its potent inhibition of 
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PDE-5, we hypothesized that such vasodilatory effect caused by cGMP in the vascular 
smooth muscle bed may potentially result in PC-like effect through affecting various 
pathways implicated in PC. This pioneering work was initiated in our lab and was first 
reported in 2002 (chapter 2). More research was conducted to elucidate the mechanism 
through which sildenafil could confer powerful acute and delayed PC-like effects.  
 
First, our results from the first study indicated the importance of mitoKATP channel 
opening in the cardioprotection afforded by sildenafil when administered at a clinically 
relevant dose; 0.71 mg/kg that was based on a 50 mg sildenafil tablet given to a 70 kg 
patient as previously discussed (chapters 2, 3,4,5,6 and 7). This was shown by the ability 
of 5-HD, a selective mitoKATP channel blocker, to completely abolish the protective effect 
of sildenafil in our well-established rabbit model. Several studies have now conclusively 
demonstrated that opening mitoKATP channels plays an important role in ischemic as well 
as pharmacological preconditioning in the heart.  KATP channels were first identified by 
cardiovascular physiology studies as causing vascular smooth muscle relaxation in either 
large or small arteries or as having a negative inotropic effect on cardiac myocytes.  In 
addition, activation of these channels seems to occur as a response to decreased 
intracellular ATP levels, which is normally achieved within a few minutes after the onset 
of ischemia. Because KATP channels act as an inward rectifier when activated, these effects 
could be caused by an increase of the depolarization threshold that reduces excitation of 
either vascular smooth muscle or cardiac myocytes followed by vasodilation and 
shortening of the action potential duration, respectively, which finally lead to intracellular 
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Ca2+ unloading and, as a result, reduced metabolic demand. Since these phenomena 
resemble the acute cardiac responses and cardioprotection afforded by ischemic PC, it has 
been postulated that mitoKATP channels might be one of the critical effectors of both 
ischemic and pharmacological preconditioning.  
In the rabbit studies (chapters 2,4 and 5), sildenafil caused an intense effect on the 
hemodynamics. However, this profound drop in blood pressure bounced back to baseline 
value within 5 minutes post treatment with sildenafil. Despite these pressure variations, 
heart rate was not considerably affected by sildenafil administration.  
In chapter 3, we further investigate the mechanism(s) through which sildenafil could cause 
a reduction in infarct size following I/R in the rabbit heart. Since PKC is a key player in 
PC, and translocation of some of its various isoforms is believed to alter several subcellular 
pathways including mitoKATP channel opening, we sought to investigate the role of PKC in 
the sildenafil induced cardioprotection. The PKC inhibitor, chelerythrine, blocked the PC-
like effect of sildenafil in rabbits (chapter 3). Furthermore, activation, i.e., translocation of 
PKC-α, -θ and -δ isoforms from cytosol to the membrane fraction after treatment with 
sildenafil was demonstrated by Western blot analysis. On the other hand, no change in 
PKC-β and -ε isoforms was observed. 
In chapter 4, we examined the cardioprotective effects of sildenafil in infant rabbits. Each 
year, more than 25,000 children endure corrective heart surgery for congenital 
cardiovascular disease. These infants are at risk for myocardial ischemia during 
cardiopulmonary bypass, circulatory arrest or low flow states which are inevitable 
components of the procedure (Rafiee et al., 2003).  Despite the data supporting the higher 
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flexibility of the infant myocardium to ischemic injury as compared to adults, the infant 
heart responds quite differently to cardiovasular drugs, stress, and changes in 
hemodynamics (Lewin et al., 1998; Wernovsky et al., 2001).  The procedures currently 
used in infants are not without limitations, such as poor functional recovery and even 
mortality. For this reason, there is a great necessity for developing pharmacological agents 
to be used as adjunct therapy along with surgical intervention in order to minimize, if not 
eradicate, the side effects shown so far. In this respect, we examined the effect of sildenafil 
on infarct size reduction as well as functional recovery following I/R in 8-week old infant 
rabbits (chapter 5). 
In addition to monitoring the hemodynamic changes as an indication of LV function , we 
assessed the left ventricular cardiac output (LVCO) and aortic velocity time integral (VTI) 
using trans-esophageal echocardiography (TEE).  Our results were analogous to those 
obtained from our adult rabbit experiments. We found that sildenafil could confer 
cardioprotection against I/R in the infant rabbit heart. Both the control and sildenafil-
treated groups had similar LVCO and aortic VTI at baseline.  However, as the TEE results 
indicated, only the sildenafil-treated group showed enhanced aortic VTI and LVCO 30 min 
following ischemia. A descent in both values was reported at 3 hr of reperfusion in all 
groups, but it was not statistically significant in the sildenafil-treated group. 
Other studies, also from our lab, were conducted using isolated mouse hearts perfused in 
Langendorff mode as previously described (chapters 3,6 and 7). Our goal was to further 
elucidate the mechanism of action of sildenafil in cardioprotection. 
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NO has been long implicated as an essential trigger and mediator of delayed PC. It has 
been also shown to be involved in physiological as well as pharmacologival PC. NO is 
synthesized by 3 isoforms of NO synthases (NOS), specifically, nNOS, iNOS and eNOS.  
Since it has been shown that NO derived from iNOS is the mediator of delayed PC, we 
tested the hypothesis that sildenafil treatment has an up-regulatory effect on iNOS leading 
to increased NO production.  Our results showed a significant reduction in infarct size 
following global I/R in the sildenafil-treated mice as compared to the corresponding 
controls 24 hr post-treatment. Also, the infarct-sparing effect of sildenafil was abolished by 
the selective iNOS inhibitor, 1400W, which had no effect on infarct size when administered 
alone.  Sildenafil treatment did not alter pre- or post-ischemic coronary flow, indicating 
that its cardioprotective effect may be independent of its vasodilatory effect in the delayed 
phase.  RT-PCR showed a transient increase in the levels of both eNOS and iNOS, peaking 
at 45 minutes (eNOS) and 2 hours (iNOS) after sildenafil treatment and returning to 
baseline levels several hours later (chapter 3), and this increase; however, was more 
profound for iNOS mRNA. Moreover, Western blot analysis revealed a significant 
increase in cardiac expression of iNOS and eNOS proteins 24 hours after sildenafil 
treatment.   These findings confirm that iNOS mediates the sildenafil-induced delayed PC 
in mice. 
The mitogen-activated protein kinase (MAPK) family has been associated with ischemic 
PC. The results; however, have been divisive. Activation of p38 by anisomycin mimicked 
PC and delayed cardioprotection in the isolated perfused hearts (Zhao et al., 2001).  In the 
MAPK family, the p42/p44-MAPK or ERK cascade appears to mediate cell growth and 
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survival signals in many cell types.  Sustained activation of p42/p44-MAPK during 
simulated 'reperfusion' following sublethal simulated ischemia mediates PC in 
cardiomyocytes independent of transient activation of p38 MAPK (Punn et al., 2000).  Our 
preliminary results (chapter 6) have shown that selective inhibition of ERK by PD98059 
completely abolished the delayed protective effect of sildenafil whereas p38 MAPK 
inhibitor SB203580 failed to block the protection.  These results were further supported by 
increased phosphorylation of p44/42 but not p38 in sildenafil treated hearts. Furthermore, 
PD98059 treatment prior to sildenafil blocked the increase of iNOS protein 24 hr later, as 
shown by Western blot analysis, indicating that sildenafil upregulates iNOS through ERK 
phosphorylation (chapter 6). 
Most recently, we tested the hypothesis that the adenosine A1 receptor plays a role in PC 
with sildenafil. The reason behind this study was that role of A1AR in PC has been 
extensively studied, but the results have been inconclusive due to the limitations of the 
A1AR antagonists.  As a result of myocardial ischemia, there is an immediate depletion in 
the ATP that is available for the cardiac cells and as a consequence adenosine is released to 
interact with its receptors. In this respect, it was believed that brief episodes of I/R would 
cause the release of adenosine and allow the interaction with its receptors to “precondition” 
the myocardium against future ischemic insults. Moreover, intracoronary infusion of 
adenosine in the isolated rabbit heart or CCPA in the isolated mouse heart prior to 
sustained I/R demonstrated a marked decrease in infarct size when compared to control 
animals. Due to the recent availability of A1AR-KO mice, the role of this receptor could 
be further examined. For this reason, we tested the role of A1AR in the infarct-limiting 
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effect of sildenafil. Our results demonstrated that the sildenafil-induced delayed protection 
was abolished in the intact heart as well as adult myocytes derived from adenosine A1 
receptor knock-out mice suggesting an essential role of A1 receptor in protection.  
Taken together, these studies suggest that sildenafil is a powerful tool to reduce I/R injury 
in the animal models studied thus far. The ongoing research effort from our lab provided a 
deeper perspective for understanding the signaling mechanisms of cardioprotection 
induced by sildenafil, apart from its well known function in causing cGMP accumulation 
in the vascular smooth muscle bed.  All these findings could be summarized as follows: 
1) increased expression of nitric oxide synthases, 2) activation of kinases (such as PKC and 
ERK), 3) opening of mitochondrial KATP channels, and 4) activation of A1AR.   
 
Conclusion and Future Directions 
 
 Since cardiovascular disease remains the number one cause of morbidity and 
mortality in the western world, it is necessary to develop novel pharmacological agents to 
be used as adjunct therapy in addition to the widely practiced surgical intervention. These 
invasive interventions are not without limitations and risks that might further damage an 
ischemic heart. Thus far, all the pharmacological agents that showed excellent 
cardioprotection in the animal models failed to do so to the same extent in human subjects. 
Since sildenafil is FDA approved, the overall safety margin of this drug has been well 
established. It is possible, due to its wide mechanism of action on the cellular and 
molecular level, that sildenafil may potentially succeed in conferring a PC-like effect 
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clinically in a similar fashion to the experimental setting. Therefore, vigilant clinical 
studies are needed to examine the role of sildenafil in PC in patients with ischemic heart 
disease.  Preliminary experimental data from our lab (data not shown) have shown that 
another PDE-5 inhibitor, Vardenafil, exerts similar PC-like cardioprotective effects in the 
rabbit heart.  Future clinical research is required to determine the safety and efficacy of 
sildenafil and other FDA-approved PDE-5 inhibitors in management of patients with 
coronary artery disease and to launch a novel cardioprotective strategy against I/R injury. 
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2. Established mouse model of ischemia/reperfusion injury via Langerdorff Mode 
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4. Hemodynamic analysis of mouse hearts via Isolated Langerdorff Method 
5. Isolation of adult mouse/rat ventricular cardiomyocytes for in vitro studies 
 
